Lesson
Airway Biology and Disease Expression
Asthma is a variable inflammatory airway disorder. Bronchoconstriction, edema, mucus, hyperresponsiveness, and structural remodeling interact, but their relative importance differs among people and across time.
- Airway inflammation
- Bronchoconstriction
- Hyperresponsiveness
- Mucus and edema
- Remodeling
Epithelium, immune cells, cytokines, edema, and mucus
Smooth muscle contraction changes expiratory flow
Repeated injury can make limitation less reversible
Follow the inflammatory signal
Airway epithelial injury and immune signaling recruit mast cells, eosinophils, lymphocytes, and other inflammatory cells. Type 2 pathways often involve IgE, interleukin 4, interleukin 5, interleukin 13, and epithelial alarmins such as TSLP. Asthma can also occur with low or suppressed Type 2 biomarkers, so one laboratory value does not define the entire disease.
Separate narrowing from inflammation
Bronchial smooth muscle contraction can narrow the airway within minutes, while mucosal edema, mucus, and inflammatory signaling prolong obstruction and increase sensitivity to triggers. A beta2 agonist may rapidly improve airflow, but symptom relief does not prove that airway inflammation or future exacerbation risk is controlled.
Understand hyperresponsiveness
Inflamed airways may constrict excessively after allergens, viral infection, exercise, cold air, smoke, occupational exposure, or irritants. The trigger does not create the diagnosis by itself. The clinical pattern still requires variable symptoms and objective evidence of variable expiratory airflow whenever confirmation is feasible.
Recognize persistent structural change
Airway remodeling can include smooth muscle growth, subepithelial fibrosis, vascular change and mucus gland enlargement, with airflow limitation that is less reversible. ICS-containing treatment reduces exacerbation risk and supports better lung-function outcomes, but do not promise that it prevents all remodeling or reverses established fibrosis. Monitor lung function even when symptoms are quiet.
Quick check
Checking for saved practice…
Lesson
Definition, Diagnosis, and Phenotype
Asthma combines variable respiratory symptoms with variable expiratory airflow. Inflammation, hyperresponsiveness, bronchoconstriction, mucus, and remodeling vary across patients and over time.
- Variable symptoms
- Variable airflow
- Bronchodilator response
- Differential diagnosis
- Type 2 phenotype
Wheeze, dyspnea, tightness, or cough change over time
Spirometry, peak flow, treatment response, or challenge
Type 2 signals, exposure, occupation, and competing disease
Require two kinds of evidence
Asthma presents with wheeze, shortness of breath, chest tightness, or cough that vary in frequency and intensity. From age 6, confirm variable expiratory airflow with spirometry before and after bronchodilator, peak-flow variability, response to inhaled corticosteroid treatment, or bronchial challenge when needed. More than one test may be required. Children 5 and younger follow the separate clinical pathway in the special-situations lesson.
Separate volume, ratio and flow
FEV1 is the volume forcibly exhaled in the first second; FVC is the total volume forcibly exhaled after a full inspiration. FEV1/FVC is their ratio, not a percentage of total lung capacity. PEF measures the highest expiratory flow, usually in L/min. These quantities answer different questions.
Prepare for bronchodilator responsiveness testing
The GINA 2026 full report measures response 10 to 15 minutes after 200 to 400 mcg salbutamol or equivalent. When clinically safe and directed by the testing clinician, withhold SABA at least four hours; formoterol or salmeterol 24 hours; indacaterol or vilanterol 36 hours; and listed long-acting muscarinic antagonists 36 to 48 hours. Do not delay urgent treatment to satisfy elective testing conditions.
Use FeNO as supporting evidence
With typical symptoms but unavailable or negative airflow testing, FeNO above 50 ppb in adults/adolescents or above 35 ppb in children can support Type 2 asthma. Other conditions also elevate FeNO, and low values do not exclude asthma. Interpret biomarkers alongside symptoms, treatment exposure and objective testing rather than as a stand-alone diagnosis.
Apply age-specific reversibility criteria
GINA 2026: for adults at least 18 years old, bronchodilator response requires FEV1 or FVC to rise at least 12% from baseline AND at least 200 mL. For ages 6 to 17, the FEV1 increase is at least 12% of predicted FEV1. Do not substitute the adult denominator for the pediatric denominator.
Calculate both adult changes
Fictional adult FEV1: 2.00 to 2.30 L gives 300 mL and 100 × 0.30/2.00 = 15%, meeting both thresholds. A change from 3.00 to 3.25 L gives 250 mL but only 8.3%, so it does not meet both. Interpret results with symptoms and test quality; a negative result alone does not exclude asthma.
Calculate a diagnostic peak-flow diary
Use the same meter morning and evening for two weeks, recording the highest of three blows each time. Daily variability is 100 × (higher minus lower PEF)/mean of the two readings; then average the daily percentages. GINA thresholds are greater than 10% for adults and greater than 13% for ages 6 to 17. For example, 360 and 440 L/min give 80/400 × 100 = 20% that day. One day is not the two-week average. PEF is less reliable than spirometry.
Test before treatment when possible
Objective confirmation becomes harder after inhaled corticosteroids improve variability. In urgent disease, treat immediately and confirm later. Record baseline FEV1, FVC, ratio, bronchodilator timing, medication withholding, effort, and test quality. A normal test on a good day does not exclude asthma.
Reassess an undocumented diagnosis on ICS
When asthma has not been confirmed, current ICS can obscure airflow variability. Use GINA's supervised diagnostic pathway, not an unsupervised treatment interruption. Document symptoms, lung function and attack risk; provide an action plan and enough medication to resume the previous dose. Avoid a diagnostic reduction during pregnancy or an unsuitable clinical period.
Use lung function to select the diagnostic branch
For typical variable symptoms without documented airflow variability on ICS, GINA separates pathways by lung function. If FEV1 or PEF is above 70% predicted, a supervised reduction with reassessment in two to four weeks may help confirm diagnosis. Below 70%, consider starting or stepping up maintenance ICS-containing treatment for one to two months, then reassess. If there is no response, return to the previous dose and refer for diagnostic investigation. These selected pathways do not replace urgent treatment or the separate pregnancy approach.
Distinguish diagnostic withdrawal from routine step-down
In selected stable patients with unconfirmed asthma, a clinician may reduce ICS by 25 to 50 percent and reassess symptoms and lung function in two to four weeks. If symptoms and variable airflow worsen, restore the previous effective treatment. If there is still no diagnostic evidence at low dose, GINA permits consideration of cessation, repeat assessment in two to three weeks and follow-up for at least 12 months. This does not authorize stopping ICS in established asthma; refer persistent uncertainty.
Challenge the diagnosis
Consider inducible laryngeal obstruction, COPD, heart failure, dysfunctional breathing, reflux, upper-airway cough, bronchiectasis, infection, pulmonary embolism, obesity, foreign body, medication effect, and deconditioning. Isolated cough has a broad differential, and wheeze is not specific.
Describe treatable traits
Type 2 inflammation may be supported by blood eosinophils, FeNO, allergy, nasal polyps, or steroid response, but biomarkers vary with treatment, smoking, infection, and comorbidity. Recent systemic corticosteroids can suppress eosinophils and FeNO; consider treatment timing when interpreting results. Low markers do not exclude asthma. Occupational pattern, obesity, aspirin-exacerbated disease, exercise, and allergic exposure can define additional traits.
Quick check
Checking for saved practice…
Lesson
Control, Risk, and Longitudinal Assessment
Few symptoms do not guarantee low risk. Every review should measure current impairment, future exacerbation and mortality risk, lung function, treatment exposure, and the patient's goals.
- Symptom control
- Exacerbation risk
- SABA exposure
- Lung function
- Adherence and technique
Four weeks: day, night, activity and symptom-driven SABA; exclude pre-exercise use
Prior attacks, low airflow, SABA exposure, and inadequate ICS
Access, adherence, technique, exposure, and comorbidity
Separate control from risk
Assess daytime symptoms, night waking, reliever use, and activity limitation over the previous four weeks. Separately assess prior severe exacerbation, low FEV1, excess SABA exposure, no or inadequate ICS, smoking or vaping, allergens, eosinophilia, pregnancy, obesity, psychosocial stress, poor access, and medication adverse effects.
Score symptoms with the right reliever rule
Over four weeks, count daytime symptoms more than twice weekly, any asthma night waking, any activity limitation, and SABA relief more than twice weekly. Exclude pre-exercise SABA; do not apply that SABA item to ICS-formoterol. Zero positive items means well-controlled symptoms, one or two partly controlled, and three or four uncontrolled.
Keep severity and medication risk distinct
Severity reflects treatment needed after several months, not symptom frequency alone. Three or more 200-dose SABA canisters yearly signals exacerbation risk; very high use, especially a canister monthly, signals mortality risk. These are review triggers, not safe-use allowances.
Treat an exacerbation as a sentinel event
An emergency visit, hospitalization, systemic corticosteroid course, intubation, or near-fatal event predicts future risk even if current symptoms are sparse. Review the trigger, treatment, discharge medicines, access, action plan, and follow-up. Review whether the prior regimen remains appropriate and address any modifiable contributors.
Plan clinical reviews separately from spirometry
For adults, adolescents and children ages 6 to 11, GINA recommends a clinical review one to three months after starting treatment, then every three to twelve months according to control, response and self-management needs. Assess asthma at other visits too. An exacerbation requires earlier review using the age-specific post-attack schedule; do not wait for the routine appointment. Pregnancy has a separate four-to-six-week monitoring schedule.
Schedule lung-function follow-up
Measure lung function before ICS treatment when feasible, again after three to six months, then at least every one to two years. Review sooner or more often for high exacerbation risk or risk of lung-function decline. A symptom-free interval does not eliminate the need for follow-up.
Measure implementation
Ask in a nonjudgmental way how often medicines are missed, inspect refill history when available, and watch the patient use every inhaler. Check inspiratory flow for dry-powder devices, coordination for metered-dose inhalers, spacer use, priming, cleaning, dose counter, storage, and affordability.
Establish a measured personal best
With the clinician, collect peak-flow readings over two to three weeks of good asthma control. Personal best is the highest valid reading in that period, not the most frequent reading or a population-predicted value. Agree on measurement timing and when to reassess the baseline. Keep the same meter for comparisons. This baseline sets action-plan zones; it is different from the mean used to calculate diagnostic daily variability.
Demonstrate peak-flow technique
Reset the indicator, stand or sit upright, inhale fully, and seal the lips around the mouthpiece without blocking it with the tongue. Exhale forcefully and quickly. Repeat a cough-affected or technically faulty attempt. Obtain three valid blows and record the highest, not their average. Compare it with the written action plan. Measurement must not delay treatment or emergency help for severe symptoms.
Calculate supply without assuming a fixed lifespan
Divide remaining usable inhalations by prescribed daily use. A device with 120 inhalations at two puffs twice daily lasts 30 days; 60 inhalations at one twice daily also lasts 30 days. As-needed use, maintenance-and-reliever use and re-priming can change depletion. Check the counter and device instructions, plus opening-date and expiration limits; medication remaining does not override a discard deadline. Arrange replacement before running out rather than assuming every rescue inhaler lasts a year.
Support smoke-free air and regular activity
At each visit, offer practical help to stop smoking or vaping and reduce secondhand exposure. Keep rooms and cars used by children free of smoke and vaping. Encourage regular physical activity with an individualized exercise-symptom plan; asthma should not lead to blanket avoidance of activity or laughter.
Target environmental changes to the patient
Do not prescribe costly universal allergen-avoidance measures to everyone with asthma. Relate symptoms to exposure and sensitization, then discuss feasible interventions and their limited or variable benefit. Address dampness or mold and reduce indoor pollutants. For sensitized patients, high-pollen alerts can guide temporary exposure reduction. Occupational sensitization requires the separate prompt removal and specialist pathway.
Keep supportive therapies in their proper role
For obesity with asthma, include supported weight management and appropriate exercise in the treatment plan. Breathing exercises may improve symptoms or quality of life but do not reliably improve lung function or reduce exacerbations. They supplement prescribed asthma therapy. Address anxiety or depression when present without attributing respiratory symptoms automatically to stress.
Review influenza protection annually
Recommend influenza vaccination each season from age 6 months, using an age-appropriate product. Inactivated injectable vaccine is suitable for asthma. Live intranasal vaccine is contraindicated at ages 2 through 4 with asthma or wheezing in the preceding year; asthma from age 5 is a precaution requiring benefit-risk assessment, not the same absolute prohibition. Some children through age 8 need two doses at least four weeks apart based on prior vaccination. Check the current seasonal schedule and other contraindications.
Distinguish pneumococcal age and risk criteria
Routine pneumococcal vaccination applies to children younger than 5 and adults from age 50. Asthma also qualifies adults 19 through 49 for risk-based assessment. For children ages 2 through 18, the asthma-specific risk criterion is moderate or severe persistent asthma. Do not extrapolate that pediatric severity threshold to adults, or assume every child with mild asthma needs an additional risk-based dose. Prior doses, other conditions and immunosuppressive treatment affect the schedule.
Use vaccination history to choose the pneumococcal sequence
For a pneumococcal-vaccine-naive adult with asthma, options are PCV20 or PCV21 alone, or PCV15 followed by PPSV23 at least one year later. The shorter eight-week minimum is reserved for specified additional risks such as immunocompromise, cochlear implant or CSF leak; asthma alone does not establish that interval. Prior vaccination changes the pathway. Check the current CDC schedule and local serotype-4 considerations before selecting a product.
Step up and down as therapeutic trials
Before stepping up, confirm diagnosis, adherence, technique, exposure, and comorbidity. Document a target and follow-up. Treat a sustained step-up as a trial: if there is no response after two to three months, return to the previous treatment level and consider alternatives or specialist referral. Worsening symptoms require earlier assessment. When control and lung function remain stable for at least about three months, consider reducing ICS exposure gradually, often by 25 to 50 percent at intervals, but do not completely stop ICS in adults or adolescents with established asthma. The supervised diagnostic pathway for an unconfirmed diagnosis is a separate exception. During pregnancy, postpone routine step-down and maintain effective ICS-containing treatment.
Quick check
Checking for saved practice…
Lesson
Airway Pharmacology and Device Selection
Relief and risk reduction come from different but complementary mechanisms. Molecule, onset, duration, device, particle delivery, and the patient's technique determine the actual dose at the airway.
- Beta2 agonism
- Inhaled corticosteroids
- LABA safety
- LAMA and leukotrienes
- Device matching
Beta2 signaling raises cyclic AMP to relax airway muscle
Repeated airway exposure suppresses inflammatory signaling
Flow, coordination, spacer, access, and preference shape dose
Relax airway smooth muscle
Beta2 agonists increase intracellular cyclic AMP to relax airway smooth muscle; onset and duration differ by agent. Albuterol is short acting. Formoterol has rapid onset with long duration, permitting selected anti-inflammatory reliever and maintenance-and-reliever strategies when combined with ICS. Other LABAs with slower onset are not substitutes for formoterol reliever regimens.
Respond to bronchodilator adverse effects
Sudden worsening immediately after inhalation can be paradoxical bronchospasm: stop the implicated product and obtain urgent assessment and alternative treatment. More frequent rescue need also requires reassessment. Beta2 agonists can cause tremor, tachycardia and intracellular potassium shifts; review cardiovascular disease, hyperthyroidism, seizures and diabetes. Do not assume levalbuterol eliminates these class effects.
Check clinically important albuterol interactions
Avoid unsupervised duplication of short-acting sympathomimetic inhalers. Loop or thiazide diuretics can compound hypokalemia and ECG effects. Beta-blockers may oppose bronchodilation or provoke bronchospasm; compelling indications need individual review. Ventolin labeling urges extreme caution with MAO inhibitors or tricyclic antidepressants, including within two weeks after stopping them. Albuterol can lower digoxin concentrations; evaluate levels when relevant, without assuming a predictable dose change because the significance during chronic inhaled use is uncertain.
Suppress airway inflammation
Inhaled corticosteroids alter gene transcription, reduce inflammatory cells and mediators, improve hyperresponsiveness, and lower exacerbation and death risk. Benefit depends on repeated airway exposure. Rinse and spit after maintenance doses when appropriate, use a spacer with compatible metered-dose ICS, and monitor dysphonia, candidiasis, growth, bone, eye, adrenal, and interaction risk according to dose and duration.
Manage local steroid effects
With fluticasone HFA, rinse and spit after inhalation. Thrush warrants antifungal treatment and technique review; controller therapy can often continue, although temporary interruption sometimes requires clinician direction. Persistent hoarseness also warrants assessment.
Assess infection exposure during corticosteroid treatment
Fluticasone HFA labeling warns that chickenpox or measles may be serious in susceptible corticosteroid-treated patients. Review immunity and counsel patients to contact a clinician promptly after exposure so preventive treatment can be assessed. Respiratory tuberculosis, systemic infections and ocular herpes simplex also require individualized review. Do not equate every inhaled dose with profound immunosuppression or advise abrupt controller withdrawal; the label notes uncertainty about how dose, route and duration affect disseminated-infection risk.
Monitor systemic effects proportionately
Measure pediatric growth routinely and use the lowest effective ICS dose. Assess bone risk and follow established monitoring standards; consider eye referral for visual symptoms or prolonged fluticasone use. Inhaled therapy can still cause adrenal suppression. Replacing long-term oral steroids requires supervised tapering and an adrenal-risk plan; good breathing does not establish adrenal recovery.
Check fluticasone metabolic interactions
Fluticasone HFA with strong CYP3A4 inhibitors such as ritonavir, ketoconazole or clarithromycin is not recommended: increased exposure can cause systemic steroid effects, including Cushing syndrome and adrenal suppression. Obtain a prescriber/pharmacist interaction review and a safe treatment plan; do not simply stop all asthma control therapy.
Classify the daily ICS exposure carefully
GINA dose categories are not equivalence or substitution tables. Confirm age, molecule, device, particle formulation and metered versus delivered convention before comparing doses. Multiply the ICS amount per inhalation by scheduled daily inhalations; count additional exposure separately when relevant. A category does not override product-specific dosing limits.
Use age-specific budesonide categories
For metered budesonide DPI doses, GINA classifies adult/adolescent daily totals of 200 to 400 mcg as low, above 400 through 800 as medium, and above 800 as high. At ages 6 to 11, the corresponding boundaries are 100 to 200, above 200 through 400, and above 400 mcg. Thus 400 mcg/day is low for an adult but medium for a child; confirm that the dose convention matches before applying this example.
Check particle formulation before classifying beclometasone
GINA's adult/adolescent metered-dose table places standard-particle beclometasone pMDI at 200 to 500 mcg/day for low dose, above 500 through 1,000 for medium and above 1,000 for high. Extrafine beclometasone instead uses 100 to 200, above 200 through 400 and above 400 mcg/day. Therefore 400 mcg/day has different categories for these formulations. This comparison is not a conversion prescription.
Distinguish the other ICS category conventions
In the same adult/adolescent table, extrafine ciclesonide uses 80 to 160, above 160 through 320 and above 320 mcg/day; fluticasone propionate DPI or pMDI uses 100 to 250, above 250 through 500 and above 500. Fluticasone furoate and mometasone do not share those boundaries. Mometasone DPI classification depends on the device. Consult the current age-specific table and product label instead of filling missing categories by analogy.
Never use LABA alone in asthma
LABA monotherapy increases serious asthma risk. Pair LABA with ICS. LAMA can modestly improve lung function and exacerbation outcomes as add-on therapy in selected uncontrolled disease. Leukotriene receptor antagonists are generally less effective than ICS and require attention to montelukast's serious neuropsychiatric warning.
Interpret the LABA warning in its treatment context
Serevent's single-ingredient salmeterol label retains an asthma-related-death boxed warning. Current Advair HFA labeling has no such box: large trials of fixed ICS-LABA combinations did not show a significant increase in serious asthma events compared with ICS alone. The trials did not exclude every possible risk. This distinction does not permit LABA-only asthma treatment, extra LABA doses, or use of Advair for acute relief.
Use a compatible holding chamber correctly
Read both inhaler and chamber instructions; dry-powder inhalers and QVAR RediHaler do not accept a spacer. For the reviewed Canadian AeroChamber Plus Flow-Vu instructions (103077-001 Rev B), ensure a tight lip or mask seal and deliver one puff at a time. With its mouthpiece, inhale slowly and deeply and hold five to ten seconds as able, or take two to three tidal breaths. With its mask, maintain the seal for five to six breaths. Follow the inhaler-specific interval before another puff.
Clean the exact chamber model
The reviewed antistatic AeroChamber Plus Flow-Vu instructions permit use straight from the package, then weekly cleaning: soak disassembled parts in mild detergent and lukewarm water for 15 minutes, rinse and air-dry before reassembly. The reviewed UK non-antistatic AeroChamber Plus instructions (117016-001 Rev B) instead require cleaning before first use and instructs leaving the detergent film without rinsing. Both specify weekly cleaning and no boiling. Regional versions can differ. Match the leaflet supplied with the actual chamber; do not turn either example into a universal spacer rule.
Inspect the chamber before use
The reviewed Flow-Vu instructions call for cleaning visible dust or debris and immediate replacement if the chamber is damaged or parts are missing. They specify replacement after 12 months of use and prohibit sharing. Keep the mouthpiece capped in a clean, dry place. A routine cleaning schedule does not justify continuing to use a damaged device.
Separate historical brands from available products
Teva discontinued marketing branded ProAir HFA on October 1, 2022. This did not mean all albuterol HFA inhalers were discontinued. An old brand entry or retained prescribing-information page does not establish present availability. Identify the actual dispensed manufacturer and device before teaching priming, cleaning or switching.
Recognize the discontinued Digihaler platform
Teva discontinued US distribution of ProAir Digihaler, ArmonAir Digihaler and AirDuo Digihaler on June 1, 2024, when its app and dashboard also became unavailable. Treat textbook descriptions of that digital platform as historical. Digihaler and RespiClick are different product names; do not extend the Digihaler notice to every similarly named inhaler. Reassess the replacement medicine, device technique and access rather than relying on obsolete app instructions.
Match the device to the person
Pressurized metered-dose, breath-actuated, dry-powder, soft-mist, nebulized, and spacer systems require different coordination and inspiratory flow. Choose around age, dexterity, cognition, inspiratory ability, preference, portability, cost, environmental impact, and the ability to demonstrate reliable use.
Quick check
Checking for saved practice…
Lesson
Aerosol and Soft-Mist Inhaler Technique
Priming, actuation, cleaning and re-priming differ even when products share an ingredient or a brand family. Identify the exact inhaler before teaching its preparation.
- Product identity
- Priming and re-priming
- Breath actuation
- Cleaning
An ingredient name does not determine priming or cleaning
Separate test sprays from prescribed treatment puffs
Check loading, actuation and inhalation together
Specify the Ventolin HFA regimen
Ventolin HFA delivers 90 mcg albuterol base per puff and is labeled from age 4. The bronchospasm regimen is two puffs every four to six hours; one every four hours may suffice for some patients. For exercise prevention, its label specifies two puffs 15 to 30 minutes beforehand. These instructions do not replace the separately taught supervised exacerbation pathway or age-specific assessment of controller need.
Prepare Ventolin HFA before treatment
Prime with four sprays away from the face before first use, after more than two unused weeks, or after dropping; shake before each spray. For treatment, inspect the mouthpiece, shake, exhale, and press while inhaling slowly and deeply. Hold about ten seconds as comfortable. Wait one minute and shake again before a second prescribed puff. Refill at counter 020; discard at 000 or expiration.
Clean and reassemble Ventolin HFA
At least weekly, remove the canister and keep it dry. Rinse the actuator with warm water for about 30 seconds in each direction; repeat if buildup remains. Shake off water and air-dry overnight. Reassemble, shake, and release one test spray away from the face. This post-cleaning spray differs from four-spray priming. If treatment is needed before complete drying, the label provides a shake-off-water, reassemble, one-test-spray sequence, followed by the prescribed dose and repeat cleaning. Keep the canister in its own actuator.
Identify the generic albuterol device
The reviewed Lupin albuterol aerosol delivers 90 mcg base per puff. Shake and prime with three sprays initially or after more than two unused weeks. Inhale slowly and deeply while pressing; hold up to ten seconds as comfortable. Before another prescribed puff, wait one minute and shake again. Its indicator estimates remaining supply rather than decrementing after every puff. Discard at zero or expiry, whichever comes first.
Clean the reviewed Lupin albuterol actuator
Weekly, remove the canister and keep it dry. Run warm water through the actuator for about 30 seconds, turn it over, and rinse through the mouthpiece for another 30 seconds. Repeat if buildup remains. Air-dry fully, reassemble, shake and give two test sprays away from the face. If urgently needed before drying, shake off water, reassemble, give two test sprays, take the prescribed dose, then rewash and dry. Keep each canister paired with its own actuator; confirm the dispensed product instructions.
Dose Xopenex HFA by its own label
Xopenex HFA is labeled from age 4. Each puff delivers 45 mcg levalbuterol free base; the usual label dose is two puffs every four to six hours. Some patients need only one puff every four hours. Increasing requirements warrant reassessment; this bronchodilator does not replace ICS when controller treatment is indicated.
Prepare and clean Xopenex HFA
Shake before use. Prime with four sprays initially or after more than three unused days. Wait about one minute between treatment puffs and shake again. Weekly, remove the canister, keep it dry, and rinse the actuator with warm water for at least 30 seconds in each direction. Air-dry overnight before reassembly. Discard at counter zero.
Handle an urgent Xopenex dose after washing
If the actuator is still wet and treatment is needed, its IFU directs shaking off excess water, replacing the canister, shaking well and releasing two sprays away from the face before the prescribed dose. Repeat the cleaning and drying sequence afterward. This exception does not replace routine overnight air-drying. Store mouthpiece down at 20 to 25 degrees C, protected from freezing, direct sunlight and excessive heat.
Prescribe Advair HFA as two inhalations
Advair HFA is labeled for asthma from age 12, using two inhalations twice daily about 12 hours apart. Strengths are 45/21, 115/21 and 230/21 mcg of fluticasone propionate/salmeterol per puff. Select by prior treatment and severity; two puffs of 230/21 twice daily is the maximum. It is not the one-puff Diskus regimen, a COPD-labeled product, or an acute reliever. Do not add another LABA.
Prime and clean Advair HFA specifically
Prime initially with four sprays; after more than four unused weeks or a drop, give two test sprays. Shake five seconds before each. Clean weekly after the evening dose with the canister retained: use a dry cotton swab at the spray opening and a water-dampened tissue inside the mouthpiece. Air-dry overnight before recapping. Do not transfer the fluticasone-only HFA damp-swab instruction to this product.
Distinguish Asmanex HFA doses
Mometasone HFA is labeled from age 5. Ages 5 to 11 use two 50 mcg inhalations twice daily, totaling the 200 mcg daily maximum. From age 12, patients not using ICS start with two 100 mcg inhalations twice daily; prior therapy and severity guide selection. Chronic oral-steroid users start with two 200 mcg inhalations twice daily, also the maximum of 800 mcg/day. Oral steroids require supervised tapering. This is maintenance treatment, not rescue.
Prepare Asmanex HFA for reliable delivery
Shake before each spray. Prime with four sprays initially and again after more than five unused days. Clean the mouthpiece inside and outside weekly with a dry, lint-free cloth or tissue; keep the canister in its own actuator. Do not wash, immerse, or clear openings with sharp objects. Rinse and spit after treatment. The dry-cleaning instructions differ from the reviewed fluticasone HFA product.
Dose fluticasone propionate HFA explicitly
For ages 4 to 11, the labeled regimen is 88 mcg twice daily: two inhalations of 44 mcg. From age 12, that is the starting regimen when not already using ICS; prior therapy and severity guide other starts. Maximum is 880 mcg twice daily. These limits belong to fluticasone propionate HFA, not every fluticasone formulation. It is maintenance, not acute rescue.
Dose QVAR RediHaler by age
At ages 4 to 11, start 40 mcg twice daily; if response is inadequate after two weeks, 80 mcg twice daily is the labeled maximum. From age 12, patients not already using ICS start 40 to 80 mcg twice daily. When switching ICS, select among 40, 80, 160 or 320 mcg twice daily based on prior therapy and severity; maximum is 320 mcg twice daily. It is not acute rescue.
Select the Alvesco dose from prior therapy
Alvesco is US-labeled from age 12. After bronchodilators alone, start 80 mcg twice daily, maximum 160 mcg twice daily. After ICS, start 80 mcg twice daily, maximum 320 mcg twice daily. After oral steroids, start and maximum are 320 mcg twice daily; supervise the systemic-steroid taper. Full benefit may take four weeks or longer. It is maintenance, not rescue.
Prepare Alvesco without shaking
Prime with three sprays away from the face before first use and after ten consecutive days without use, following the patient instructions. Shaking is unnecessary. Press while inhaling slowly and deeply, then hold about ten seconds as comfortable. Rinse and spit. Clean the mouthpiece inside and outside weekly with dry tissue, including the outlet area; do not immerse or wash the unit.
Recognize the breath-actuated aerosol exception
QVAR RediHaler is an aerosol activated by inhalation, not a conventional press-and-breathe device. Do not prime, shake, or attach a spacer. Close the cap to prepare each inhalation, then open it when ready. Exhale away, seal lips around the mouthpiece, inhale deeply with the device upright, and hold for five to ten seconds before exhaling away. Close the cap between prescribed inhalations. Rinse and spit afterward. Wipe the mouthpiece weekly with a dry tissue or cloth; do not wash it.
Use and clean fluticasone propionate HFA
Shake five seconds, exhale, then press while inhaling slowly and deeply; hold about ten seconds as comfortable. Wait 30 seconds before the next prescribed puff and shake again. Rinse and spit. Clean weekly after the evening dose without removing the canister: gently clean the spray opening with a water-dampened cotton swab, repeating with a fresh swab if needed. Wipe inside the mouthpiece with a water-dampened tissue, air-dry overnight, then recap. Follow the dispensed product instructions; other aerosol inhalers have different cleaning methods.
Prime fluticasone propionate HFA separately
The reviewed HFA label requires four initial sprays, shaking five seconds before each. After more than seven unused days or dropping, shake and give one test spray away from the face. A compatible valved holding chamber and mask can assist young patients. Do not apply the one-spray re-priming rule to Dulera.
Specify Dulera maintenance strength
Dulera contains mometasone/formoterol. Ages 5 to 11 use two 50/5 mcg inhalations twice daily, totaling 200/20 mcg daily. From age 12, use two 100/5 or 200/5 mcg inhalations twice daily according to prior treatment and severity; the maximum totals 800/20 mcg daily. These are labeled maintenance doses. Formoterol content alone does not establish a reliever regimen: do not substitute these doses into the budesonide-formoterol AIR/MART instructions. Dulera labeling calls for a separate short-acting reliever and prohibits additional LABA therapy.
Use and clean Dulera correctly
Shake before each puff, coordinate pressing with a slow deep inhalation, and hold up to ten seconds as comfortable. Wait at least 30 seconds before the second puff and shake again. Rinse and spit after both puffs. Weekly, wipe the mouthpiece inside and outside with dry lint-free material, retaining the canister in the actuator. Do not wash or use a sharp object to unblock it. Refill at counter 20; discard at zero or expiry.
Prime Dulera for the exact device
Dulera requires four test sprays before first use and four again after more than five days without use. Shake before each test spray and direct it away from the face. These sprays prepare the inhaler; they are not inhaled treatment doses. Do not transfer another brand's priming count to this device.
Separate Symbicort label dosing from the action plan
Conventional Symbicort labeling specifies two 80/4.5 mcg inhalations twice daily at ages 6 to 11. From age 12, use two 80/4.5 or 160/4.5 inhalations twice daily; the latter is the labeled maximum. COPD uses two 160/4.5 inhalations twice daily. These are US maintenance-label schedules. Guideline-directed AIR/MART is a separately prescribed regimen, as explained in the strategy lesson; do not combine its as-needed instructions with an unrelated maintenance plan or assume every formulation shares the same limits.
Read Aerosphere dose versus puff strength
For asthma from age 12, Symbicort Aerosphere uses two inhalations of 80/4.8 or 160/4.8 mcg twice daily. Thus each administration delivers a labeled total of 160/9.6 or 320/9.6 mcg, respectively; these totals are not single-puff strengths. Selection depends on control, severity and current ICS treatment. Adult COPD uses two 160/4.8 inhalations twice daily. Its label limits use to two inhalations twice daily and does not authorize acute relief. Confirm the exact formulation when interpreting a prescription or action plan.
Identify the Symbicort device before counseling
For the conventional Symbicort 80/4.5 or 160/4.5 aerosol, prime with two test sprays away from the face, shaking for five seconds before each. Repeat after more than seven unused days or if dropped. Clean the mouthpiece inside and outside weekly with a dry cloth; do not immerse or dismantle this inhaler.
Track budesonide-formoterol opening dates
Both reviewed Symbicort products are discarded three months after foil-pouch opening or at counter zero, whichever comes first. Date opening even when use is intermittent. A canister that still sprays after zero does not establish a reliable dose; never float it in water to estimate supply. Store at room temperature away from heat; conventional Symbicort is stored mouthpiece down. For Aerosphere, order a replacement when its indicator enters the yellow zone. Match each canister to its own actuator.
Recognize the Aerosphere instructions
Symbicort Aerosphere uses four initial test sprays and two re-priming sprays after more than seven unused days, dropping, or weekly actuator rinsing; shake before each. Remove the canister and keep it dry. Rinse the actuator with warm water through the mouthpiece for 30 seconds and through the top for 30 seconds. Shake off water, repeat rinsing if buildup remains, and air-dry fully before reassembly. Do not towel-dry. Replace the cover, insert the canister, then re-prime. Its April 2026 US label covers asthma from age 12, not acute relief. Check the exact product before applying a treatment plan.
Match Breztri strength to indication
Breztri Aerosphere combines budesonide, glycopyrrolate and formoterol. From age 12, asthma maintenance uses two 160/18/4.8 mcg puffs twice daily. Each administration totals 320/36/9.6 mcg. COPD uses 160/9/4.8 mcg per puff. Do not use Breztri for rescue or add another LABA; avoid duplicate anticholinergics.
Prepare the Breztri device
Shake before each puff. Prime initially with four sprays; re-prime with two after dropping, more than seven unused days, or rinsing. For the 120-puff canister, remove and keep the canister dry during weekly actuator rinsing: warm water for 30 seconds through each opening, then air-dry fully and re-prime. Rinse and spit after treatment. Discard at zero or three months after opening; the 28-puff canister has a three-week limit.
Prepare and use Spiriva Respimat
After cartridge insertion, direct test sprays toward the ground until mist appears, then repeat three more times. After more than three but no more than 21 unused days, release one test spray; after more than 21, repeat the initial mist-plus-three sequence. For each treatment puff, turn the base halfway with the cap closed until it clicks, open, exhale away, and press while inhaling slowly and deeply without blocking the vents. Hold for up to ten seconds as comfortable. Repeat for the second prescribed puff. Clean the mouthpiece, including its inner metal part, weekly with a damp cloth or tissue. Avoid spraying into the eyes.
Date and replace the Spiriva Respimat
At cartridge insertion, write the three-month discard date specified in the IFU. Replace sooner if the device empties and locks, and arrange a refill when the indicator reaches the red area. Do not force the locked base or remove the assembled cartridge. Store at 20 to 25 degrees C and avoid freezing. Children should use the inhaler with adult assistance.
Quick check
Checking for saved practice…
Lesson
Dry-Powder Inhaler Technique
A dry-powder dose must be loaded correctly and inhaled with the device-specific technique. Moisture, wasted doses and excipient allergy require separate attention.
- Loading
- Inspiratory technique
- Moisture
- Counter interpretation
- Excipient allergy
A lever, twist or cap prepares the dose
Exhale away, then use the instructed inspiratory technique
Counter movement and taste alone do not prove delivery
Keep Serevent with its asthma controller
Serevent Diskus contains salmeterol 50 mcg per inhalation. From age 4, its asthma dose is one inhalation twice daily, about 12 hours apart, only with concurrent ICS when ICS alone is inadequate. It is not acute rescue. A fixed ICS-LABA product ordinarily helps ensure both components are taken in children and adolescents.
Distinguish salmeterol exercise prevention from rescue
The labeled exercise-prevention dose is one inhalation at least 30 minutes before exercise. Do not repeat for 12 hours, and do not add an exercise dose to twice-daily Serevent. The label allows selected isolated EIB use without persistent asthma; this does not justify LABA-only asthma treatment.
Check salmeterol-specific safety and storage
Do not combine Serevent with another LABA. Severe milk-protein hypersensitivity contraindicates this powder. Strong CYP3A4 inhibitors such as ritonavir or ketoconazole are not recommended with salmeterol because exposure and cardiovascular risk increase. Discard Serevent six weeks after foil opening or at counter zero, whichever comes first.
Identify all three Trelegy components
Trelegy Ellipta contains fluticasone furoate, umeclidinium and vilanterol: ICS, LAMA and LABA. Its asthma indication begins at age 18. Use one inhalation daily of 100/62.5/25 or 200/62.5/25 mcg; prior therapy, severity, control and exacerbation risk guide selection. The latter is the asthma maximum. Only 100/62.5/25 is labeled for COPD. Neither strength is an acute reliever or MART product.
Review duplication and anticholinergic precautions
Trelegy should not be combined with another LABA, and its label advises avoiding other anticholinergic-containing drugs. Reconcile existing inhalers when switching so a previous Breo or tiotropium prescription is not inadvertently continued. Use caution with narrow-angle glaucoma or urinary retention. Eye pain with blurred vision or halos, or painful or difficult urination, requires immediate clinical assessment. Severe milk-protein hypersensitivity is a contraindication. Use once per 24 hours and rinse and spit afterward.
Match Breo Ellipta strength to age and indication
Breo combines fluticasone furoate with vilanterol. Asthma dosing is one inhalation daily: 50/25 mcg at ages 5 to 11, 100/25 mcg at ages 12 to 17, and 100/25 or 200/25 mcg in adults. Adult strength selection depends on previous therapy and severity; 200/25 daily is the adult maximum. The COPD regimen is 100/25 daily. Do not substitute the adult asthma maximum for pediatric or COPD dosing. Severe milk-protein hypersensitivity is a contraindication.
Keep Breo as scheduled maintenance
Use at the same time daily, never more than once in 24 hours. Breo is not an acute reliever or a MART inhaler; do not add another LABA-containing product. Keep the prescribed reliever available. Rinse and spit after use. Record tray opening and discard after six weeks or at counter zero, whichever comes first. Reassess worsening symptoms instead of taking extra Breo inhalations.
Demonstrate Breo and Trelegy Ellipta loading
Slide the cover down until it clicks only when ready to inhale; this loads a dose and advances the counter. Do not shake. Closing before inhalation wastes the prepared dose. Exhale away, seal the mouthpiece without covering the vent, and take a long, steady, deep breath. Hold for about three to four seconds as comfortable, then breathe out gently. Do not repeat because no medicine was tasted. Close the cover and rinse and spit; use a dry tissue on the mouthpiece only if needed.
Check Ellipta supply and device function
For Breo and Trelegy, contact the pharmacist or prescriber if opening produces a click without the counter decreasing; the instructions warn that medicine will not be delivered. A red area appears when fewer than ten doses remain, prompting a refill. Both products are discarded six weeks after tray opening or at zero, whichever comes first. Record both dates and keep the inhaler dry at room temperature, away from heat and sunlight.
Select the Twisthaler schedule by age and prior therapy
Asmanex Twisthaler is mometasone powder. Ages 4 to 11 use 110 mcg each evening, the maximum regardless of prior therapy. From age 12, prior bronchodilator-only or ICS treatment calls for a 220 mcg evening start; maximum is 440 mcg/day, either each evening or divided as 220 mcg twice daily. Prior oral-steroid treatment calls for 440 mcg twice daily, the 880 mcg/day maximum, with supervised steroid tapering. It is not rescue treatment and is contraindicated with milk-protein hypersensitivity.
Load and preserve Twisthaler correctly
Hold upright while twisting the cap off counterclockwise; cap removal loads the dose. Exhale away, place the mouthpiece horizontally, and inhale rapidly and deeply without covering vents. Hold about ten seconds as comfortable. Dry-wipe if needed, then replace the cap clockwise until it clicks; rinse and spit. Do not wash. Discard 45 days after pouch opening or once the counter reaches zero and the final loaded dose has been inhaled, whichever comes first.
Dose fluticasone propionate Diskus separately
For patients not using ICS, the labeled starting dose is 50 mcg twice daily at ages 4 to 11 and 100 mcg twice daily from age 12. Prior treatment and severity guide other starts. After two weeks of inadequate response, reassess treatment; age-specific maxima are 100 and 1,000 mcg twice daily, respectively. These are prescription limits, not targets for self-escalation. Severe milk-protein allergy is a contraindication. This product provides maintenance treatment, not rescue.
Protect fluticasone Diskus doses and storage
Use the level, lever-loaded Diskus technique described below; load each prescribed inhalation separately. Do not repeat simply because powder was not tasted. Keep dry and do not wash or attach a spacer. Record pouch opening: discard the 50 mcg device after six weeks, but the 100 and 250 mcg devices after two months, or earlier at counter zero. Do not assume that every Diskus product has the same discard interval.
Keep Arnuity once daily
Arnuity Ellipta contains fluticasone furoate. Ages 5 to 11 use one 50 mcg inhalation daily. From age 12, start at 100 mcg daily if not using ICS; other starts depend on prior therapy and severity. Maximum is 200 mcg daily. Severe milk-protein hypersensitivity is a contraindication. It is not rescue treatment.
Dose Flexhaler by age and strength
For ages 6 to 17, labeled starting treatment is 180 mcg twice daily; some start at 360 mcg twice daily, the maximum. From age 18, start at 360 mcg twice daily, although 180 mcg twice daily may suffice; maximum is 720 mcg twice daily. For example, 360 mcg requires two inhalations of the 180 mcg strength, not two of either strength. It is maintenance treatment, not rescue. Severe milk-protein allergy is a contraindication.
Separate Flexhaler priming from dose loading
Before first use only, hold Pulmicort Flexhaler upright and turn its brown grip fully one way and back, then repeat that cycle to prime. Next load the first dose with a separate full back-and-forth cycle. No later re-priming is required. Exhale away, then inhale deeply and forcefully through the mouthpiece. Do not shake a loaded device or repeat a dose merely because nothing was felt. Replace the cover and rinse and spit. Clean the mouthpiece exterior weekly with a dry tissue; keep water out.
Interpret Flexhaler loading and its indicator
Repeated grip turns still prepare only one dose, but continue advancing the indicator and can make it understate the remaining supply. The display is approximate: movement may become visible only after about five doses, with markings at ten-dose intervals. If you accidentally exhale into a loaded Flexhaler, its instructions say to load a new dose. Do not use a damaged inhaler or one with a detached mouthpiece; contact the pharmacist or prescriber. Do not remove or twist the mouthpiece.
Load and protect Arnuity Ellipta
Open the cover only when ready; closing without inhaling wastes that dose. Exhale away, then inhale deeply and steadily through the mouth without blocking the vent. Hold about three to four seconds as comfortable. Do not repeat because no powder was tasted. Close, rinse and spit. Dry-tissue cleaning is optional when needed. Discard six weeks after tray opening or at counter zero, whichever comes first.
Choose the Advair Diskus strength
At ages 4 to 11 with asthma uncontrolled on ICS, use one 100/50 mcg inhalation twice daily. From age 12, use one 100/50, 250/50 or 500/50 inhalation twice daily, selected by prior therapy and severity; 500/50 twice daily is the asthma maximum. COPD uses 250/50 twice daily. Doses are about 12 hours apart, with no additional LABA or rescue use. Discard one month after pouch opening or at zero, whichever comes first.
Keep AirDuo RespiClick doses distinct
AirDuo is labeled for asthma from age 12: one inhalation twice daily about 12 hours apart. For less severe asthma without current ICS, the starting strength is 55/14 mcg. Greater severity or prior ICS exposure can require 113/14 or 232/14 mcg; the latter twice daily is the maximum. Strength selection follows prior ICS treatment and severity, not a puff-for-puff substitution for Advair HFA or Diskus. This is maintenance therapy, not rescue; avoid another LABA.
Load Advair Diskus without wasting the dose
Open the Diskus, hold it level, and slide the lever fully until it clicks. Keep it level and open until inhalation; do not move the lever again. Exhale away, seal your lips, inhale quickly and deeply, then hold for about ten seconds as comfortable. Close the device and rinse and spit. Do not repeat a dose merely because powder was not tasted. Keep it dry, do not wash or dismantle it, and do not attach a spacer.
Teach Inhub loading independently
Wixela contains fluticasone propionate/salmeterol. Lower the mouthpiece cover and hold Inhub vertically while pushing its yellow lever fully down to the arrow ends. Leave it open without moving the lever again. Exhale away, inhale quickly and deeply, then hold about ten seconds as comfortable. Close the cover afterward; this resets the lever and decrements the counter. Rinse and spit. Do not repeat merely because powder was not tasted, wash the device, or use a spacer.
Confirm Wixela strength and remaining supply
Use one inhalation twice daily: 100/50 mcg for ages 4 to 11 with asthma uncontrolled on ICS; from age 12 select 100/50, 250/50 or 500/50 by prior treatment and severity, with 500/50 twice daily the maximum. COPD uses 250/50 twice daily. The red indicator appears at nine remaining doses. Discard one month after pouch opening or at zero, whichever comes first. It is not rescue treatment, and severe milk-protein allergy is a contraindication.
Specify ProAir RespiClick dosing and allergy restrictions
This albuterol powder delivers 90 mcg of base per inhalation and is labeled from age 4. The bronchospasm schedule is two inhalations every four to six hours; one every four hours may suffice for some patients. For exercise prevention, use two inhalations 15 to 30 minutes beforehand. Severe milk-protein hypersensitivity or albuterol hypersensitivity contraindicates this product. Increasing need requires reassessment rather than self-escalation. Follow the prescribed asthma plan and its anti-inflammatory treatment; this dose schedule does not replace the supervised exacerbation pathway.
Use RespiClick cap loading correctly
AirDuo RespiClick and ProAir RespiClick need neither priming nor a spacer. Starting with the cap closed, hold upright and open fully until it clicks only when ready for a dose. Exhale away, seal the mouthpiece without covering the vent, inhale quickly and deeply, then hold for about ten seconds as comfortable. Close firmly after each inhalation. AirDuo also requires rinsing and spitting afterward. A counter change reflects device operation, not proof of correct lung delivery; observe technique instead of relying on the number alone.
Protect dry powder from water
For AirDuo and ProAir RespiClick, clean the mouthpiece only with a dry cloth or tissue when needed. Replace the inhaler if washed or immersed; simply drying it is not the labeled remedy. AirDuo is discarded 30 days after pouch opening, at zero, or at expiry, whichever comes first. ProAir RespiClick has a different pouch-opening limit of 13 months, also subject to zero and expiry. Record the exact product and opening date.
Screen for the relevant excipient allergy
Advair Diskus is contraindicated in severe milk-protein hypersensitivity because its lactose-containing powder contains milk proteins. Check the actual product ingredients and allergy history before choosing a device; a familiar active ingredient does not establish that every formulation is suitable.
Quick check
Checking for saved practice…
Lesson
Nebulized Drug Preparation and Storage
The prescribed drug amount, concentration, final chamber volume and delivery system are separate checks. Storage limits also depend on which container has been opened.
- Dose versus volume
- Concentrate dilution
- Jet nebulizer
- Opened-container limits
The drug amount remains 2.5 mg after dilution
2.5 mg divided by 5 mg/mL gives 0.5 mL
0.5 mL drug plus 2.5 mL saline gives 3 mL
Match the aerosol generator to the medicine
A nebulizer converts liquid medication into an inhalable aerosol delivered through a mouthpiece or fitted mask during breathing. Jet, ultrasonic and mesh devices generate that aerosol differently. A prescription for a nebulized drug does not establish that every device is suitable. Check the medicine and device instructions together, including compressor requirements, fill volume and cleaning; poor mask fit can reduce delivery.
Prepare the prescribed Xopenex concentrate dose
For the 1.25 mg/0.5 mL concentrate, the instructions add 2.5 mL sterile normal saline unless the prescriber directs a different volume. The usual mixture totals 3 mL and still contains 1.25 mg. Gently swirl the chamber. Do not confuse this with albuterol 0.5%, which contains a different drug amount in the same 0.5 mL volume.
Distinguish the two Xopenex storage rules
For ready-to-use 3 mL Xopenex vials, use within two weeks after opening the foil pouch. An unopened vial removed from that pouch must remain protected from light and be used within one week, without extending the original pouch deadline. In contrast, the concentrate label requires use immediately after opening its foil pouch. Store both at 20 to 25 degrees C, protected from light and excessive heat; discard discolored solution. These are product-specific instructions, not a shared rule for every generic levalbuterol package.
Use age-specific nebulized levalbuterol doses
Xopenex solution is labeled from age 6. Ages 6 to 11 start at 0.31 mg three times daily; routine dosing should not exceed 0.63 mg three times daily. From age 12, start at 0.63 mg three times daily, six to eight hours apart; selected patients may need 1.25 mg three times daily with closer adverse-effect monitoring. These label regimens are distinct from a supervised emergency protocol.
Do not split Xopenex concentrate for a smaller dose
The concentrate contains 1.25 mg in 0.5 mL and requires sterile normal saline dilution before jet nebulization. Its label requires the non-concentrated 3 mL formulation for doses below 1.25 mg. Do not derive a pediatric partial-vial concentrate instruction from concentration arithmetic alone. Mixing compatibility with other nebulized drugs is not established.
Distinguish nebulizer concentration from dose
For a prescribed 2.5 mg albuterol nebulizer dose, the 0.083% product supplies 2.5 mg in a ready-to-use 3 mL vial; no dilution is required. The 0.5% concentrate supplies 2.5 mg in 0.5 mL and requires sterile normal saline to a total of 3 mL: add 2.5 mL, not 3 mL. A small unit-of-use vial can still be concentrated. Read the exact product strength and instructions.
Recognize lower-strength albuterol unit doses
Aurobindo albuterol 0.63 mg/3 mL and 1.25 mg/3 mL are prediluted products labeled for ages 2 to 12. The starting label regimen is one matching-strength vial three or four times daily as needed. No dilution is required; use a jet nebulizer. These products were not studied for acute attacks. Do not substitute their labeled schedule for an emergency protocol or let recurring bronchodilator use replace controller reassessment.
Keep storage instructions specific to the package
For these Aurobindo lower-strength vials, store at 2 to 25 degrees C with protection from light and excessive heat. Keep sealed vials in their foil pouch; once removed, use within one week. Discard discolored solution. This is not permission to retain an opened vial for a week. Check the dispensed label rather than transferring a different manufacturer's pouch deadline.
Use the 2.5 mg product within its labeled scope
Ritedose 0.083% albuterol contains 2.5 mg per 3 mL ready-to-use vial. It is labeled from age 2. Its usual labeled regimen is one vial three or four times daily for adults and children weighing at least 15 kg. The label directs children below 15 kg needing less than 2.5 mg to a different formulation rather than a partial vial. Patient-specific acute-care dosing is a separate protocol. Keep this product in its light-protective pouch until use and store at 2 to 25 degrees C.
Check the dilution independently
0.5% weight/volume means 0.5 g/100 mL = 5 mg/mL. A 2.5 mg dose therefore occupies 2.5/5 = 0.5 mL. Adding 2.5 mL saline changes the volume, not the 2.5 mg drug amount. Filling the chamber with 3 mL of undiluted concentrate would contain 15 mg. These are preparation examples, not a universal dose or acute-care schedule. Follow product and nebulizer instructions; do not assume compatibility with other drugs in the chamber.
Dose Respules from the prior treatment
US-labeled maintenance use is ages 12 months through 8 years. After bronchodilators alone, the table starts and tops out at 0.5 mg/day, given once or split as 0.25 mg twice daily. After inhaled steroids, start at the same daily dose, with a 1 mg/day maximum. After oral steroids, start at 1 mg/day, once or as 0.5 mg twice daily, also the maximum. A 0.25 mg once-daily start may be considered for symptomatic children not responding to non-steroidal therapy. Titrate down after stability; systemic-steroid withdrawal requires supervision.
Prepare Pulmicort Respules for the right delivery system
Pulmicort Respules is a maintenance budesonide suspension, not acute rescue. Use a compressed-air jet nebulizer with an appropriate mouthpiece or fitted mask; ultrasonic delivery is not recommended. Administer separately from other nebulized medicines. Gently mix the ampule with a circular shaking motion, open upright, and squeeze its contents into the cup. Rinse and spit after treatment; wash the face after mask use.
Read milligrams as well as ampule volume
Every Respules strength contains 2 mL, but the drug amount is 0.25, 0.5 or 1 mg. A prescribed 0.5 mg dose requires the 0.5 mg/2 mL ampule when using one full ampule. Volume alone cannot identify the dose.
Distinguish the envelope clock from the ampule clock
Store Respules upright at room temperature, protected from light. Date the opened foil envelope and return unused sealed ampules to it; discard them after two weeks. An opened ampule must be used immediately. The two-week allowance does not apply to an opened ampule.
Quick check
Checking for saved practice…
Lesson
Adjunct Drugs, Safety, and Monitoring
Add-on medicines target different pathways and carry different monitoring burdens. Their role is narrower than core inhaled corticosteroid-containing treatment, and benefit must be weighed against toxicity, interactions, and treatment complexity.
- LAMA
- Leukotriene modifiers
- Theophylline
- Systemic corticosteroids
- Medication triggers
Reduce vagal bronchoconstriction with a selected short or long role
Check agent-specific mood, liver and interaction precautions
Theophylline and corticosteroids demand toxicity surveillance
Add muscarinic blockade selectively
GINA 2026 supports adding ipratropium to SABA for short-term treatment of moderate or severe exacerbations, with reassessment after initial treatment. Tiotropium and other approved long-acting muscarinic options can be added for persistent uncontrolled asthma in appropriate ages and devices, but expected benefit is generally modest. Review anticholinergic effects, glaucoma exposure, urinary retention, device use, and duplication.
Recognize OTC inhaled epinephrine's limited role
Primatene Mist contains epinephrine 0.125 mg per spray. Its label permits temporary relief of mild intermittent asthma symptoms from age 12 after a doctor's asthma diagnosis. OTC availability does not establish adequate inflammation control or replace the ICS-containing strategy taught here. This oral-inhalation product is not interchangeable with nasal or injected anaphylaxis treatment.
Screen before OTC bronchodilator self-treatment
Primatene Mist must not be used with an MAOI or within two weeks after stopping one. Cardiovascular disease and prior asthma hospitalization require clinician review. Worsening, no improvement within 20 minutes, more than two attacks weekly, or needing over eight inhalations daily warrant medical assessment. Severe breathing difficulty requires emergency care.
Specify the asthma tiotropium strength
US Spiriva Respimat labeling for asthma from age 6 specifies two inhalations of 1.25 mcg each once daily: 2.5 mcg total. COPD uses two inhalations of 2.5 mcg each: 5 mcg total. Verify indication, strength and device instead of copying a COPD prescription. This is maintenance treatment, not rescue; maximal asthma lung-function benefit may take four to eight weeks.
Monitor anticholinergic exposure
Respimat requires no routine renal dose adjustment, but creatinine clearance below 60 mL/min requires close anticholinergic monitoring. New painful or difficult urination, or eye pain with blurred vision or halos, needs immediate assessment. Check for duplicate anticholinergic drugs. Tiotropium or ipratropium hypersensitivity contraindicates this product.
Use leukotriene therapy with an explicit safety conversation
Montelukast blocks the cysteinyl leukotriene receptor and may help selected patients with asthma, exercise-related symptoms, allergic rhinitis, or aspirin-exacerbated respiratory disease. It is generally less effective than ICS for preventing exacerbations. FDA requires a boxed warning for serious neuropsychiatric events, so discuss behavioral and mood changes before prescribing. If new neuropsychiatric symptoms occur, stop montelukast and contact a clinician immediately. Monitor after discontinuation because symptoms can persist. For allergic rhinitis, reserve it for inadequate response or intolerance to alternatives.
Use indication-specific montelukast dosing
For asthma, dose once each evening: age 15 years or older, 10 mg tablet; ages 6 to 14, 5 mg chewable; ages 2 to 5, 4 mg chewable or granules; ages 12 to 23 months, 4 mg granules. It does not treat an acute attack. For exercise prevention at age 6 or older, use the age-appropriate dose at least two hours beforehand. Do not add an exercise dose to daily therapy or repeat within 24 hours.
Prepare montelukast granules immediately before use
Give the full 4 mg packet directly into the mouth, in 5 mL of cold or room-temperature formula or breast milk, or in a spoonful of cold or room-temperature applesauce, carrots, rice, or ice cream. Open only when ready and administer within 15 minutes. Do not dissolve in juice or other liquids, save a mixture, or retain leftovers. Drinks may follow the dose.
Check the montelukast formulation in phenylketonuria
Singulair chewable tablets contain aspartame: the reviewed 4 mg tablet supplies 0.674 mg phenylalanine and the 5 mg tablet supplies 0.842 mg. Include this in the total daily phenylalanine assessment for a patient with phenylketonuria. Check the exact manufacturer and formulation before applying these amounts to another product.
Recognize montelukast treatment boundaries
Do not abruptly replace inhaled or oral corticosteroids with montelukast. Evaluate eosinophilia accompanied by vasculitic rash, worsening respiratory symptoms, cardiac complications or neuropathy, particularly during oral-steroid reduction; a causal relationship to montelukast has not been established. Montelukast does not make aspirin or NSAID exposure safe in a patient with known aspirin sensitivity.
Separate enzyme findings from montelukast dose decisions
Montelukast inhibits CYP2C8 in laboratory experiments, but a clinical probe study did not demonstrate that effect in people. Do not treat it as a proven clinical CYP2C8 inhibitor. Gemfibrozil increased montelukast exposure 4.4-fold in a study; nevertheless, Singulair labeling requires no montelukast dose adjustment with this combination.
Monitor montelukast response with lumacaftor/ivacaftor
Orkambi may lower montelukast exposure and reduce its effectiveness. Its labeling recommends clinical monitoring without a montelukast dose adjustment. Review asthma control and the treatment plan if symptoms worsen; do not automatically increase montelukast above its age-specific labeled dose.
Distinguish zafirlukast from montelukast
Zafirlukast dosing is 20 mg twice daily from age 12, or 10 mg twice daily at ages 5 to 11. Take it at least one hour before or two hours after meals because food reduces absorption. Hepatic impairment, including cirrhosis, is a contraindication. Suspected liver dysfunction requires stopping zafirlukast and immediate liver testing, especially ALT. Do not resume after confirmed hepatic dysfunction or re-expose after otherwise unexplained drug-associated liver injury. Its warfarin interaction requires close anticoagulation monitoring. It is not an acute rescue drug.
Protect zafirlukast during storage
Dispense in the original airtight container and protect the tablets from moisture and light. The reviewed product label specifies storage at 20 to 25°C. Include these instructions when counseling about the separate empty-stomach dosing requirement.
Review additional zafirlukast risks
Report new insomnia or depression for a benefit-risk review. Investigate eosinophilia with vasculitic rash, worsening breathing, cardiac symptoms or neuropathy, especially during steroid reduction; causation is not established. Studies did not show increased theophylline exposure, but rare increases and toxicity have been reported. Monitor rather than assuming either no interaction or a predictable dose change. Theophylline and erythromycin can lower zafirlukast exposure; fluconazole can increase it.
Prescribe zileuton with its monitoring plan
Zileuton inhibits leukotriene synthesis. The extended-release regimen from age 12 is two 600 mg tablets twice daily within one hour after morning and evening meals, totaling 2400 mg/day; swallow whole. Check ALT before treatment, monthly for three months, every two to three months for the rest of year one, then periodically. Active liver disease or persistent enzymes at least three times the upper limit of normal contraindicate use. Stop for liver symptoms or transaminases at least five times the upper limit, with follow-up until normal. When starting zileuton in a theophylline user, its label calls for roughly halving theophylline and monitoring concentrations. With warfarin, monitor coagulation, including INR, and titrate warfarin to the measured response. With propranolol, monitor for increased beta blockade and reduce propranolol if needed; do not extrapolate a fixed dose reduction to all beta blockers. Report sleep or behavior changes. Zileuton is not rescue treatment.
Distinguish immediate-release zileuton
Zyflo immediate-release dosing from age 12 is 600 mg four times daily, totaling 2400 mg/day; meals and bedtime can aid scheduling. The same daily milligrams as extended-release therapy do not imply the same dosing interval. Active liver disease or transaminases at least three times the upper limit contraindicate use. Check ALT before treatment, monthly for three months, every two to three months for the remainder of year one, then periodically. The immediate-release label directs stopping for liver symptoms or transaminases greater than five times the upper limit and following levels until normal; the extended-release label uses at least five times. Both require clinical assessment of abnormal results. Keep the exact formulation on the prescription.
Respect narrow therapeutic exposure
Theophylline inhibits phosphodiesterase and has other airway effects, but GINA 2026 does not recommend oral theophylline for asthma because of adverse-effect risk. The following label details support review of existing therapy, not preferred treatment selection. Fever, smoking changes, liver or heart disease, age, and CYP inhibitors can raise exposure. Nausea, tremor, tachyarrhythmia, and seizures may signal toxicity and require urgent evaluation.
Separate ipratropium label and acute asthma use
Atrovent HFA is FDA-labeled for COPD maintenance, not initial rapid rescue. Guideline-directed ipratropium added to a rapid bronchodilator during selected asthma exacerbations is a different use; follow the acute-care protocol rather than importing the COPD maintenance schedule. It does not replace ICS or the primary reliever. Avoid eye exposure and review narrow-angle glaucoma, urinary retention and duplicate anticholinergics.
Review named theophylline interactions
Ciprofloxacin, cimetidine, fluvoxamine, erythromycin and clarithromycin can increase theophylline exposure. Rifampin, carbamazepine and phenytoin can reduce it; stopping an inducer can reverse that effect. Theophylline can increase lithium clearance, and its interaction with phenytoin can lower both concentrations. Check both starting and stopping medicines, measure concentrations appropriately and individualize changes. The label's interaction table is historical and not exhaustive; an unlisted new drug is not proven compatible.
Qualify exposure-raising interactions
Theo-24 labeling also identifies disulfiram, estrogen-containing oral contraceptives, methotrexate, pentoxifylline, propafenone, propranolol and verapamil as exposure-raising interactions. Its allopurinol entry specifies doses at least 600 mg/day; the alcohol entry describes a single large intake, not every drinking pattern. Table percentages are study averages, not automatic dose adjustments. Review the actual exposure and obtain appropriately timed concentrations.
Review supplements and stopping dates
Phenobarbital and St. John’s wort can lower theophylline concentrations. Stopping an inducer can then cause accumulation and toxicity. Conversely, stopping an inhibitor may reduce concentrations. Ask about supplements and recently stopped medicines, not just the current prescription list.
Do not predict ritonavir interactions from one enzyme
Ritonavir labeling reports decreased theophylline concentrations and recommends considering therapeutic monitoring; a higher dose may be needed. This differs from its exposure-raising interaction with inhaled fluticasone. Do not make an automatic adjustment or extrapolate the studied ritonavir regimen to every combination or short treatment course.
Recognize related anticonvulsant interactions
Primidone can reduce theophylline concentrations through enzyme induction. Fosphenytoin becomes phenytoin, so phenytoin interaction review also applies to it. Reconcile these names explicitly and monitor response and concentrations when therapy changes; do not assume an injection lacks the oral drug’s interaction potential.
Interpret thyroid replacement through thyroid status
In hypothyroidism, theophylline clearance may be reduced. Levothyroxine labeling explains that clearance returns toward normal as euthyroidism is restored. Reassess theophylline during this transition instead of treating levothyroxine as a universal fixed-percentage inducer.
Consider changing physiology and diet
Beyond smoking and fever, the label associates reduced clearance with acute pulmonary edema, cor pulmonale, shock, hypothyroidism and high-carbohydrate/low-protein diets. Hyperthyroidism, cystic fibrosis, high-protein/low-carbohydrate diets and daily charcoal-broiled beef may increase clearance. Use changes as reasons to reassess concentrations; do not prescribe dietary manipulation as asthma treatment.
Support smoking cessation with concentration monitoring
Changes in marijuana smoking also warrant review. Stopping tobacco smoking can reduce theophylline clearance and raise exposure on the same dose. Arrange monitoring and dose review while supporting cessation. Theo-24 labeling reports no clearance effect from nicotine gum; gum should not be assumed to preserve the metabolic effect of smoking. Also review sustained fever, heart failure, liver disease and thyroid status when concentrations change.
Do not turn the loading-dose entry into routine rescue
The oral-solution label describes a 5 mg/kg immediate-release loading dose only as a temporary measure when inhaled or parenteral beta agonists are unavailable and no theophylline was taken in the prior 24 hours. This is not an extended-release loading instruction. GINA does not recommend oral theophylline for asthma, and the module's acute-care pathway uses recommended inhaled treatment instead.
Anticipate nonlinear theophylline exposure
Theophylline metabolism can become capacity-limited, so a small dose increase may produce a disproportionately large concentration increase. This can occur within the therapeutic range; there is no universal concentration at which every patient switches to nonlinear elimination. Use small, monitored adjustments rather than assuming dose and concentration rise proportionally. Caffeine and 3-methylxanthine are active metabolites, with age and renal function affecting their accumulation.
Review conditions that theophylline can worsen
The reviewed label calls for extreme caution with active peptic ulcer disease, seizure disorders, and cardiac arrhythmias other than bradyarrhythmias. These concerns are separate from conditions that reduce drug clearance. Review both the patient’s underlying disease and exposure-related toxicity risk before continuing therapy.
Specify the weight used in theophylline calculations
The reviewed oral labels base mg/kg calculations on ideal body weight because theophylline distributes poorly into body fat. Document the selected dosing weight rather than silently using total body weight. In a calculation exercise that explicitly supplies a 60 kg dosing weight, 5 mg/kg gives 300 mg. This arithmetic illustrates the historical immediate-release loading entry; it does not recommend theophylline for acute asthma or establish a dose without the formulation, prior exposure and clinical review.
Individualize Theo-24 initiation
For adults ages 16 to 60 without impaired-clearance risks, Theo-24 labeling starts at 300 to 400 mg/day, then permits 400 to 600 mg/day after at least three days if tolerated. Further adjustment requires concentrations and response. This is not a universal 300 to 600 mg maintenance range. Reduced-clearance risks or inability to monitor impose lower ceilings; the label generally limits these adults to 400 mg/day. Older adults require particular caution.
Respect formulation and meal timing
Theo-24 once-daily dosing is taken consistently in the morning, not at night. Rapid metabolizers may require a clinician-selected divided regimen. At doses at least 900 mg or 13 mg/kg, whichever is less, avoid taking it less than one hour before a high-fat meal because exposure can rise. These are exact-product instructions, not a reason to change another theophylline formulation without review.
Interpret theophylline ranges in context
Theo-24 labeling describes bronchodilation across 5 to 20 mcg/mL and generally favors peaks of 10 to 15 mcg/mL for benefit versus risk. Its sampling section also gives an expected peak range of 5 to 15 mcg/mL. These statements do not establish one universal target or justify automatic escalation for a value below 10. Consider response, toxicity, formulation and timing. With reduced protein binding, measure unbound drug; the label specifies 6 to 12 mcg/mL for unbound concentrations.
Convert aminophylline on the stated basis
For an exercise explicitly using the rounded 0.8 factor, aminophylline mg multiplied by 0.8 gives theophylline mg; divide by 0.8 for the reverse conversion. Thus 250 mg approximates 200 mg, and 200 mg divided by 0.8 is 250 mg. Actual injection labeling specifies 25 mg/mL aminophylline dihydrate equivalent to 19.7 mg/mL anhydrous theophylline: 10 mL contains 197 mg theophylline. Use the supplied product equivalence when exact content is requested. This calculation does not establish a treatment indication: GINA advises against IV aminophylline or theophylline for asthma exacerbations.
Time theophylline levels to the question
For Theo-24 dose-increase decisions, labeling specifies a sample 12 hours after dosing at steady state, usually after three consistent days. Do not apply this timing to every formulation. A low trough can conceal a higher peak; check product, dose history and sampling time before increasing treatment.
Act immediately on suspected theophylline toxicity
Repetitive vomiting or other compatible toxicity symptoms require withholding further doses, immediate serum testing and urgent evaluation, even if another cause seems possible. Do not wait for the usual sampling time. Acute worsening of asthma is not a reason to increase theophylline. Concentration targets require product and patient context; a reported therapeutic total level does not exclude toxicity when protein binding is reduced.
Limit systemic corticosteroid harm
Short systemic corticosteroid courses can be lifesaving in significant exacerbations, but cumulative exposure contributes to hyperglycemia, infection, mood effects, hypertension, bone loss, cataract, adrenal suppression, and other harm. Repeated courses should trigger a prevention review, optimization of inhaled treatment, and specialist evaluation when appropriate.
Quick check
Checking for saved practice…
Lesson
Stepwise Controller and Reliever Strategy
Adults, adolescents and children 6 to 11 need an ICS-containing strategy; younger children have a separate pathway. GINA Track 1 uses low-dose ICS-formoterol as the adult and adolescent reliever across steps, while Track 2 uses an ICS-containing alternative when Track 1 is unavailable or unsuitable.
- AIR-only
- MART
- Track 2
- ICS-SABA
- US-label distinction
AIR-only for Steps 1 and 2, MART for Steps 3 through 5
ICS-SABA or daily ICS-containing control plus reliever
Match evidence to product, age, device, jurisdiction, and limit
Choose the starting step from the presentation
For adults and adolescents, GINA favors as-needed low-dose ICS-formoterol when symptoms are infrequent or occur less than most days with normal or mildly reduced lung function. Symptoms on most days, asthma-related waking at least weekly, or low lung function favor starting low-dose MART. Assess these features together with exacerbation risk and the patient’s ability to use and obtain treatment.
Recognize presentations needing more initial treatment
Daily symptoms or at least weekly night waking combined with low lung function or a recent exacerbation favor medium-dose MART. If the first presentation is an acute exacerbation, treat that episode and start medium-dose MART; the Track 2 alternative is medium-dose ICS-LABA with the appropriate reliever. These are adult/adolescent starting recommendations, not a substitute for urgent assessment or the separate childhood pathway.
Prefer anti-inflammatory relief
GINA 2026 Track 1 prefers low-dose ICS-formoterol for relief in adults and adolescents because it reduces severe exacerbations compared with SABA-reliever regimens. Steps 1 and 2 use as-needed AIR-only therapy. Steps 3 through 5 use maintenance ICS-formoterol plus the same inhaler as needed, called MART.
Use Track 2 when it fits better
Track 2 includes an ICS-containing reliever strategy or daily ICS-containing controller plus reliever. GINA 2026 adds as-needed low-dose ICS-SABA as an adult and adolescent Step 1 alternative. FDA-labeled albuterol-budesonide is an as-needed rescue product for adults and is not maintenance therapy. At Step 1 with separate ICS and SABA inhalers, take ICS whenever SABA is used.
Distinguish the Track 2 reliever options
At Step 1, ICS-SABA alone as needed is also AIR-only. If only SABA is available, pair each use with ICS. At Steps 2 through 5, daily ICS-containing maintenance continues with the chosen reliever; a SABA-only reliever requires reliable maintenance adherence. Do not confuse a SABA-only reliever within that regimen with SABA-only treatment.
Dose albuterol-budesonide by puffs and doses
Airsupra is US-labeled for adults at least 18 years old: two puffs as needed deliver albuterol 180 mcg plus budesonide 160 mcg. Maximum: six doses, or 12 puffs, per 24 hours. Persistent symptoms or increased need require reassessment; do not wait to reach the maximum before seeking help. Rinse and spit after use if water is available.
Prime this device correctly
For Airsupra, prime with four sprays away from the face, shaking before each. Re-prime with two sprays after more than seven unused days, dropping, or cleaning. Discard at counter zero. These instructions are product-specific.
Keep guideline and label distinct
GINA is an international evidence strategy. US labels define approved product use. Current US budesonide-formoterol maintenance labels state that the product is not a rescue inhaler, although GINA supports ICS-formoterol AIR and MART using evidence-based formulations. Clinicians must apply local regulation, formulary, product strength, device, age, and maximum inhalation instructions.
Specify the budesonide-formoterol regimen
GINA 2026 uses delivered 160/4.5 mcg per inhalation from age 12: one as needed for AIR-only; Step 3 MART adds one once or twice daily; Steps 4 to 5 use two twice daily plus relief. Count maintenance and relief together; needing more than 12 inhalations in 24 hours requires medical care. Worsening symptoms can require help earlier. These are guideline regimens, not universal product-label instructions.
Apply the pediatric AIR update
For ages 6 to 11, GINA includes AIR-only budesonide-formoterol. Its delivered 80/4.5 mcg regimen uses one as needed; Step 3 MART adds one daily, Step 4 one twice daily. More than eight total inhalations in 24 hours requires medical care. GINA does not recommend Step 5 MART for ages 6 to 11. Check local approval and device suitability.
Check the formulation before counting inhalations
GINA does not recommend budesonide-formoterol 320/9 mcg delivered dose as an anti-inflammatory reliever. The 80/4.5 strength is the recommended pediatric AIR strength, but is not GINA's recommended adult/adolescent AIR formulation. For ICS-formoterol delivered by pMDI, GINA recommends a spacer. Match the actual delivered versus metered dose; the device label may report them differently.
Do not transfer the ceiling to a lower-formoterol product
Some countries have budesonide-formoterol 80/2.25 mcg delivered per puff. GINA uses two puffs per relief dose for that formulation, with different maintenance puff counts and a medical-care threshold above 24 total puffs in 24 hours. This exception does not change the 12-inhalation threshold for 160/4.5. Confirm the prescribed product rather than doubling an unrelated inhaler.
Reconcile a controller transition
When replacing an ICS-only inhaler with an ICS-LABA, confirm the intended stop/start instructions and reconcile remaining inhalers so the old ICS is not continued accidentally. Demonstrate the new device. Fluticasone-salmeterol remains scheduled maintenance, not rescue; retain the specifically prescribed reliever. A switch to MART instead requires an explicit ICS-formoterol maintenance-and-relief plan. Do not infer rescue use merely because a new inhaler combines two drugs.
Interpret refill concerns before changing treatment
Frequent symptom-driven SABA use and activity restriction indicate a control problem, but refill dates alone cannot establish technique or adherence. Ask about daytime symptoms, night waking and actual use; observe delivery and assess access, triggers and future risk before selecting a step-up. Reconcile the intended regimen with the prescriber and agree on follow-up rather than automatically adding another inhaler.
Escalate only after fundamentals
For persistent uncontrolled disease, verify exposure and implementation, then progress from low-dose to medium-dose ICS-formoterol MART or an alternative ICS-LABA strategy. Add LAMA or refer for phenotype assessment at higher steps rather than repeatedly increasing SABA or oral corticosteroid exposure.
Quick check
Checking for saved practice…
Lesson
Children, Special Situations, and Severe Asthma
Age, pregnancy, exercise, occupation, aspirin sensitivity, and phenotype alter treatment. Severe asthma is a retrospective diagnosis after high-dose optimized care still fails or is required to maintain control.
- Children 6 to 11
- Preschool wheeze
- Pregnancy and exercise
- Difficult-to-treat asthma
- Biologic phenotype
Verify diagnosis, adherence and technique; address contributing factors
Allergy, eosinophils, FeNO, polyps, dermatitis, and steroid burden
IgE, IL-5 or its receptor, IL-4R alpha, or TSLP; reassess response
Use age-specific pathways
Children 6 to 11 should not receive SABA-only treatment. GINA 2026 Step 1 options include as-needed low-dose ICS-formoterol, ICS-SABA, or ICS taken whenever SABA is used. Daily ICS and selected ICS-LABA or MART regimens apply at higher steps. Check local approval and device ability; a guideline option does not establish a pediatric US product indication. For children 5 and younger, use the separate clinical diagnostic criteria and treatment pathway below.
Review the child before stepping up
Check technique, adherence, exposures and comorbidities first. If as-needed ICS-formoterol is insufficient, GINA identifies low-dose MART as the next step. Consider pediatric specialist referral when Step 4 is needed; persistent symptoms or attacks despite correctly used Step 4 treatment require expert assessment.
Confirm preschool asthma clinically
GINA requires all three elements in children 5 and younger: recurrent acute wheezing, no likely alternative explanation, and timely improvement with asthma treatment. The symptom criterion is at least two acute wheezing episodes in the past 12 months, or one episode with interval symptoms. Count episodes lasting more than 24 hours and confirm wheeze at least once through a trained clinician or a convincing caregiver description or recording; other noisy breathing is not equivalent. If only one or two diagnostic elements are present, document suspected asthma and reassess rather than forcing an adult spirometry criterion.
Document the treatment response
A qualifying preschool response can be improvement within 20 to 60 minutes of SABA, within three to four hours after starting SABA plus systemic corticosteroid for a more severe episode, or improvement during a two- to three-month daily ICS trial with as-needed SABA. Record the observed or convincingly caregiver-reported response and reassess competing diagnoses if improvement is absent.
Choose preschool treatment by symptoms and attacks
For selected children 5 and younger with symptoms no more than twice weekly, as-needed inhaled SABA may be sufficient. Daily low-dose ICS is indicated when symptoms are not well controlled or when an episode in the past year required acute care, oral corticosteroid or hospitalization. Assess an initial ICS trial over two to three months. Do not transfer the school-age AIR or MART regimen into this younger group.
Escalate preschool treatment deliberately
Before stepping up, reconfirm diagnosis, technique, adherence and exposures. GINA Step 3 considers doubling the low daily ICS dose, with reassessment after two to three months and consideration of specialist referral. Persistent poor control, attacks or adverse effects require expert assessment. Intermittent high-dose ICS for selected viral-triggered episodes is a clinician-directed option with adverse-effect risk, not a routine caregiver-initiated substitute for daily controller assessment.
Distinguish the NAEPP intermittent preschool plan
NAEPP conditionally supports a seven- to ten-day ICS course plus as-needed SABA at respiratory-infection onset for selected children aged 0 to 4: at least three infection-triggered wheezing episodes ever or two in the past year, no symptoms between infections, and no daily asthma treatment. A clinician-provided plan can authorize caregivers to start at home with clear instructions. Monitor growth and reassess whether ongoing controller treatment is needed; this is a defined recurrent-wheeze strategy, not unsupervised escalation of any child's ICS.
Treat pregnancy and exercise without withholding control
Continue effective ICS-containing treatment during pregnancy because exacerbations and hypoxemia threaten both parent and fetus. Review asthma every four to six weeks during pregnancy; avoid bronchial challenge testing and defer diagnostic confirmation requiring it until after delivery. ICS-formoterol can be used before exercise in the relevant strategy, or a reliever can be taken before activity, while persistent exercise symptoms trigger review of baseline control and differential diagnosis.
Act on occupational sensitization
Ask about workplace exposures in adult-onset asthma. Once occupational sensitization is established, remove further exposure promptly; simply increasing inhalers does not address the cause. Refer suspected cases for expert assessment because diagnosis and workplace changes have important consequences.
Recognize aspirin-exacerbated respiratory disease
Asthma with recurrent nasal polyps and respiratory reactions to aspirin or NSAIDs suggests AERD. Avoid COX-1 inhibitors in affected patients. Diagnostic challenge and aspirin desensitization require specialist facilities. Acetaminophen or a selective COX-2 inhibitor may be considered with healthcare-provider supervision and at least two hours of observation after administration, not assumed universally safe. Continue ICS-containing treatment; desensitization adds gastrointestinal and bleeding risks.
Review medication triggers without blanket bans
Ask about eye drops as well as oral drugs. NSAIDs are not universally contraindicated in asthma without prior reactions. Beta-blockers can cause bronchospasm, but a compelling cardiovascular indication requires individual assessment. Cardioselective beta-blockade for acute coronary events is not absolutely excluded; specialist supervision and benefit-risk review are needed.
Select allergy immunotherapy deliberately
Confirm that sensitization matches clinically relevant exposure and symptoms; a positive allergy test alone is insufficient. Immunotherapy is an adjunct, not rescue treatment. NAEPP 2020 conditionally supports subcutaneous immunotherapy (SCIT) from age 5 for mild-to-moderate allergic asthma controlled during initiation, dose escalation and maintenance. Do not administer SCIT during asthma symptoms or to patients with severe asthma under this guidance. Use a supervised clinic equipped for anaphylaxis and observe for at least 30 minutes after each injection; never administer asthma SCIT at home.
Distinguish sublingual guidance from approval
NAEPP 2020 conditionally recommends against sublingual immunotherapy (SLIT) specifically for persistent allergic asthma. GINA 2026 considers house-dust-mite SLIT in sensitized adults and adolescents with persistent symptoms despite low- or medium-dose ICS-containing therapy, only with FEV1 greater than 70% predicted. GINA also considers ragweed SLIT for sensitized children before and during the season when FEV1 is at least 80% predicted, but finds insufficient evidence for house-dust-mite SLIT in childhood asthma. These recommendations do not establish a US asthma indication.
Apply the house-dust-mite tablet label
Odactra is FDA-approved at ages 5 through 65 for confirmed house-dust-mite allergic rhinitis with or without conjunctivitis, not as an asthma treatment or immediate symptom reliever. Its first dose requires supervised administration and at least 30 minutes of observation. Prescribe epinephrine, teach its use, and instruct patients to stop treatment and seek immediate care if epinephrine is needed. Severe, unstable or uncontrolled asthma, prior severe systemic allergy or severe local SLIT reaction, eosinophilic esophagitis history, and ingredient hypersensitivity are contraindications.
Hold SLIT when safety changes
Withhold Odactra during an acute asthma exacerbation; recurrent exacerbations require reassessment and possible discontinuation. Pause it for oral wounds or inflammation until healed. Persistent or severe swallowing difficulty or chest pain requires stopping treatment and evaluation for eosinophilic esophagitis. These are product-specific precautions, not permission to self-start another allergen formulation.
Separate treatment difficulty from severe asthma
Difficult-to-treat asthma includes poor control despite prescribed medium/high-dose ICS-LABA or maintenance oral steroids, and asthma requiring high-dose treatment to stay controlled. Correctable delivery, adherence, exposure or diagnostic problems may explain the difficulty. Severe asthma is the subset that remains uncontrolled after good adherence, optimized high-dose ICS-LABA and management of contributors, or needs that optimized regimen to maintain control. A high-dose prescription alone does not establish severe asthma.
Treat comorbidities for their demonstrated role
Treat symptomatic reflux, but do not prescribe reflux therapy solely for poorly controlled asthma without reflux symptoms. Treat allergic rhinitis alongside asthma; improvement in nasal symptoms does not guarantee improved asthma control. Include weight management when obesity contributes to treatment difficulty.
Fix difficult-to-treat asthma first
Before severe-asthma labeling, reconfirm diagnosis, inhaler technique, adherence, access, smoking and vaping, occupational exposure, allergens, obesity, rhinosinusitis and polyps, reflux, sleep apnea, mental health, medication triggers, and treatment intensity. Distinguish uncontrolled disease from true treatment resistance.
Match biologic to phenotype and label
Omalizumab targets IgE-mediated allergic asthma. Anti-IL-5 or IL-5 receptor therapies target eosinophilic disease. Dupilumab blocks IL-4 receptor alpha signaling in Type 2 disease, and tezepelumab targets upstream TSLP with broader eligibility. Product age, biomarkers, exacerbations, steroid dependence, comorbid polyps or dermatitis, dosing, response, adverse effects, payer rules, and current labels determine selection.
Quick check
Checking for saved practice…
Lesson
Targeted Biologic Therapies
Match the inflammatory target, age, regimen, administration setting and safety plan for each biologic.
- IL-5 ligand and receptor
- IL-4 receptor alpha
- TSLP
- Long-interval therapy
A cytokine and its receptor are different binding targets
Related mechanisms do not make doses interchangeable
Home use depends on the exact device and patient selection
Distinguish cytokine binding from receptor binding
Mepolizumab and reslizumab bind the IL-5 cytokine, preventing its interaction with the receptor. Benralizumab instead binds IL-5 receptor alpha on eosinophils and basophils and promotes antibody-dependent cellular cytotoxicity. These are related pathways with different molecular targets; they are not three interchangeable IL-5 receptor blockers.
Explain the shared IL-4 receptor subunit
Dupilumab binds IL-4 receptor alpha, a shared component of receptor complexes involved in IL-4 and IL-13 signaling. It therefore inhibits both pathways; IL-3 is not the target described in its label. Naming the binding target and the affected signals separately avoids conflating a receptor with its cytokines.
Dose mepolizumab by asthma age group
Nucala is add-on maintenance for severe eosinophilic asthma from age 6. Give 40 mg subcutaneously every four weeks at ages 6 to 11 and 100 mg every four weeks from age 12. The pediatric 40 mg prefilled syringe requires caregiver or healthcare-professional administration. Home injection requires clinician approval and training. The reconstituted vial is prepared and administered by a healthcare professional. Consider zoster vaccination when medically appropriate.
Prepare mepolizumab vial doses by final concentration
A professional reconstitutes the Nucala vial with 1.2 mL sterile water for injection, producing 100 mg/mL. Gently swirl without shaking. Withdraw 1 mL for 100 mg or 0.4 mL for 40 mg; discard unused contents. If not used immediately, keep below 30 degrees C without freezing and discard eight hours after reconstitution. Do not mix with other medications.
Distinguish mepolizumab prefilled handling clocks
Store prefilled devices refrigerated in their carton. An unopened carton may remain outside refrigeration at up to 30 degrees C for seven days; once a device leaves the carton, use within eight hours. Allow 30 minutes at room temperature before injection, without external heating. Do not shake, freeze or use a device dropped on a hard surface. Give a missed dose as soon as possible, then resume the usual day; if the next dose is already due, administer as planned.
Apply the pediatric benralizumab threshold
Fasenra asthma labeling now begins at age 6. At ages 6 to 11, use 10 mg below 35 kg or 30 mg at 35 kg or more; from age 12, use 30 mg. Give subcutaneously every four weeks for three doses, then every eight weeks. A child receiving doses at weeks 0, 4 and 8 next receives a dose at week 16. The prefilled syringe is for healthcare-professional administration. The 30 mg pen requires appropriate training; at ages 6 to 11 it is an option only at 35 kg or more and is administered by a caregiver or professional.
Prepare and store benralizumab by its own instructions
Keep Fasenra refrigerated at 2 to 8 degrees C in its carton. Allow about 30 minutes at room temperature before injection. Once brought to room temperature, use within 14 days at no more than 25 degrees C or discard. Do not freeze, shake or heat. Check the prescribed 10 mg or 30 mg presentation. Small translucent or white particles may be normal; cloudy, discolored solution or large or foreign particles require rejection.
Keep reslizumab an observed infusion
Cinqair is add-on maintenance for severe eosinophilic asthma from age 18: 3 mg/kg intravenously every four weeks over 20 to 50 minutes, not IV push. Its boxed anaphylaxis warning requires administration and observation by a professional prepared to manage the reaction. Stop the infusion and treat immediately if anaphylaxis occurs; permanently discontinue. For a 70 kg adult, 3 mg/kg gives 210 mg. At 10 mg/mL, withdraw 21 mL for dilution; this is not the final infusion volume.
Prepare reslizumab as a filtered infusion
Add the calculated concentrate volume slowly to a bag containing 50 mL of 0.9% sodium chloride; gently invert without shaking. Discard unused vial contents. Use a 0.2-micron low-protein-binding in-line filter of a labeled compatible material. Do not co-infuse other drugs through the same line. After infusion, flush with 0.9% sodium chloride to deliver the remaining drug.
Track reslizumab preparation time and safety signals
Use the diluted infusion immediately when possible. Otherwise, protect it from light at 2 to 8 degrees C or room temperature up to 25 degrees C, with no more than 16 hours between preparation and administration. Allow refrigerated solution to reach room temperature before infusion. Malignancies were observed more often in treated trial participants than controls; this observation alone does not establish causation. Report concerning symptoms and reassess treatment as clinically indicated.
Preserve safety when adding eosinophil-directed therapy
Mepolizumab, benralizumab and reslizumab do not treat acute bronchospasm. Do not abruptly stop inhaled or systemic corticosteroids when starting them. Treat existing helminth infection first; hold the biologic if an infection develops and fails appropriate antihelminth therapy until it resolves. Mepolizumab and benralizumab can cause hypersensitivity, including reactions delayed for days; discontinue the responsible product if a reaction occurs and arrange appropriate treatment. Known hypersensitivity to the selected drug or its excipients contraindicates use. Calling their adverse effects merely minor omits clinically important risks.
Check dupilumab indication and pediatric weight
Dupixent is add-on maintenance from age 6 for moderate-to-severe eosinophilic or oral-corticosteroid-dependent asthma. At ages 6 to 11, the asthma regimen is 300 mg subcutaneously every four weeks at 15 to less than 30 kg, or 200 mg every two weeks at 30 kg or more, without loading. The table supplies no regimen below 15 kg.
Recognize the dermatitis dosing exception
For ages 6 to 11 with asthma and moderate-to-severe atopic dermatitis, use the dermatitis schedule instead: at 15 to less than 30 kg, load 600 mg then 300 mg every four weeks; at 30 to less than 60 kg, load 400 mg then 200 mg every two weeks; at 60 kg or more, load 600 mg then 300 mg every two weeks.
Choose the adolescent or adult dupilumab regimen
From age 12, asthma dosing is 400 mg loading then 200 mg every two weeks, or 600 mg then 300 mg every two weeks, subcutaneously. Select the latter for oral-steroid dependence, moderate-to-severe atopic dermatitis, or chronic rhinosinusitis with nasal polyps. Comorbid allergic fungal rhinosinusitis also selects it in adults, and in adolescents aged 12 to 17 who weigh at least 60 kg.
Counsel for dupilumab-specific risks
Dupilumab is not rescue treatment; taper corticosteroids only under supervision. Suspected eosinophilic pneumonia or eosinophilic granulomatosis with polyangiitis (EGPA) warrants assessment and consideration of withholding treatment. Stop for significant hypersensitivity. Report new or worsening eye, skin or joint symptoms. Suspected keratitis or conjunctivitis/blepharitis that persists despite standard treatment warrants consideration of discontinuation and prompt ophthalmologic examination. Treat helminths first; discontinue for unresponsive infection until resolved. Labeling advises avoiding live vaccines. Asthma trials did not show the increased conjunctivitis frequency seen in dermatitis.
Handle delayed dupilumab doses using the current label
For every-two-week or every-four-week dosing, administer a missed dose within seven days and retain the original schedule. If more than seven days have passed, administer it and start a new schedule from that date. Do not substitute an older instruction to skip the delayed dose.
Prepare dupilumab for the intended recipient
Keep it refrigerated at 2 to 8 degrees C in its carton. After removal, use within 14 days at no more than 25 degrees C or discard. Do not freeze, shake or heat. Before injection, allow 45 minutes for 300 mg or 30 minutes for 200 mg, with the cap on. At asthma ages 6 to 11, a caregiver injects; adolescents require adult supervision. Loading injections use different sites.
Place tezepelumab in current severe-asthma care
GINA 2026 includes anti-TSLP tezepelumab as add-on treatment from age 12 when severe asthma remains uncontrolled despite high-dose ICS-LABA. It is no longer a therapy awaiting guideline inclusion. Confirm severe disease after addressing technique, adherence and contributing conditions; check local eligibility.
Distinguish tezepelumab devices
Tezspire dosing is 210 mg subcutaneously every four weeks from age 12. Its US asthma indication does not require an eosinophilic phenotype. The vial and prefilled syringe require professional administration; the pen permits patient or caregiver use after clinician approval and training. Allow about 60 minutes to reach room temperature; do not heat, shake or return it to refrigeration afterward.
Track tezepelumab storage and missed doses
Store Tezspire at 2 to 8 degrees C in its carton. After removal, use within 30 days at 20 to 25 degrees C or discard; once at room temperature, do not refrigerate again. Do not freeze. For a missed dose, administer as soon as possible and resume the usual administration day; if the next dose is already due, give it as planned.
Keep tezepelumab safety separate from rescue care
It does not treat acute attacks. Known product hypersensitivity contraindicates use; reactions, including anaphylaxis, may be delayed for days. Treat reactions promptly and reassess continuation. Avoid abrupt corticosteroid withdrawal and live attenuated vaccines. Treat helminths before starting; discontinue for unresponsive infection until resolved. Common asthma-trial adverse effects include pharyngitis, arthralgia and back pain.
Interpret the tezepelumab cardiac signal carefully
The long-term extension trial reported more serious cardiac adverse events with tezepelumab than placebo, with varied event types. The separate adjudicated major cardiovascular-event comparison had a confidence interval that included no difference. Recognize the reported signal without treating these different endpoints as equivalent or claiming that the trial proves a specific cardiac injury mechanism.
Recognize the six-month IL-5 option
Depemokimab-ulaa (Exdensur) is add-on maintenance for severe eosinophilic asthma from age 12. A healthcare professional administers 100 mg subcutaneously every six months. It is not home self-injection or acute rescue treatment. After a missed dose, give it as soon as possible and count the next six-month interval from the actual administration date.
Keep depemokimab protected until preparation
Store Exdensur at 2 to 8 degrees C in its carton, protected from light. An unopened carton may remain outside refrigeration for up to seven days at no more than 30 degrees C. Once the syringe leaves the carton, the eight-hour use limit applies. Do not freeze, shake or expose to heat.
Prepare and monitor depemokimab appropriately
Allow the prefilled syringe 30 minutes at room temperature without external heat. Do not shake or expel its normal air bubble; discard if outside the carton beyond eight hours. Inject within five minutes of cap removal. Hypersensitivity requires discontinuation and treatment. Avoid abrupt steroid withdrawal. Treat helminths first; discontinue for unresponsive infection until resolved. Common trial adverse effects included respiratory infections, allergic rhinitis, arthralgia and pharyngitis.
Measure benefit after biologic initiation
For adolescents and adults, GINA recommends review at three to four months, then every three to six months. Compare attacks, symptoms, lung function, steroid exposure, comorbid disease, adverse effects and patient experience. No single response cutoff is established. An uncertain response may justify extending the trial to six to twelve months; absent benefit warrants stopping and considering another eligible therapy.
Reduce treatment cautiously after improvement
With sustained benefit, prioritize supervised oral-steroid tapering and assess adrenal suppression. Confirm stability after each change. Consider removing add-on LAMA before lowering ICS-LABA. After at least three to six months of good control on a biologic, an ICS dose reduction may be tried with monitoring and reversal if control worsens; maintenance ICS-containing treatment should continue.
Separate ineffective treatment from withdrawal after success
Stopping a biologic for lack of benefit differs from a planned withdrawal after good response. GINA consensus generally defers a withdrawal trial until at least 12 months of treatment, with asthma still controlled on medium-dose ICS-containing therapy and, in allergic asthma, no ongoing exposure to the documented trigger. Relapse can occur after stopping; arrange specialist follow-up and maintain ICS-containing treatment.
Quick check
Checking for saved practice…
Lesson
Omalizumab Dosing and Safety
Use the correct asthma table, distinguish presentations, and assess anaphylaxis risk before home administration.
- Pretreatment IgE
- Age and weight
- Presentation
- Anaphylaxis
Match age, weight and pretreatment IgE
The same milligram dose may have a different interval
Vial and prefilled volumes and site instructions differ
Confirm omalizumab asthma eligibility
Xolair labeling covers age 6 or older with moderate-to-severe persistent asthma, perennial aeroallergen sensitization by skin or in-vitro testing, and inadequate control on ICS. Guideline treatment-step placement and FDA eligibility are distinct.
Use the asthma dose table
Select 75 to 375 mg subcutaneously every two or four weeks using pretreatment total IgE, weight and the age-specific asthma table. Do not substitute another indication table. Adjust for significant weight changes; on-treatment total IgE cannot guide redosing.
Read the omalizumab interval as well as the dose
For asthma initiation, an adult weighing 70 kg with pretreatment IgE 250 IU/mL maps to 225 mg every two weeks. A 9-year-old weighing 35 kg with the same IgE maps to 225 mg every four weeks. Read both table axes and interval shading; do not extrapolate into cells without a recommended dose.
Reassess omalizumab after an interruption
Total IgE may remain elevated for up to one year after stopping. For an interruption shorter than one year, use the original pretreatment IgE for dosing. At one year or longer, remeasure total IgE. Apply current weight and the appropriate asthma age table; do not automatically restart an old dose.
Assess omalizumab home administration individually
Start in a healthcare setting prepared for anaphylaxis and observe for an appropriate period after administration; risk persists beyond a year. Teach patients to recognize symptoms and seek immediate medical care if they occur. Asthma home-use selection includes no prior anaphylaxis to Xolair or other agents, including foods; at least three supervised doses without hypersensitivity; and ability to recognize and treat anaphylaxis and inject correctly. Three tolerated doses alone are insufficient.
Match omalizumab device to age
For asthma ages 6 to 11, a caregiver administers the prefilled syringe; Xolair autoinjectors are not intended below age 12. Adolescents may use either prefilled presentation under adult supervision after appropriate selection and training.
Keep vial and prefilled volumes distinct
A 300 mg prefilled device delivers 2 mL in one injection. A 300 mg dose from reconstituted vials requires two injections totaling 2.4 mL: each vial delivers 150 mg/1.2 mL, with no more than 150 mg per site. Multiple injections are spaced at least one inch apart. The vial is prepared and administered only by a healthcare professional. Do not transfer its concentration or site limit to prefilled devices.
Distinguish reconstitution from the administered volume
For each lyophilized Xolair vial, add 1.4 mL sterile water for injection and gently swirl; do not shake. Follow the labeled intermittent swirling sequence and discard if not fully dissolved by 40 minutes. The administered 150 mg volume is 1.2 mL, not the volume of water added. Protect reconstituted vials from sunlight; use within eight hours refrigerated at 2 to 8 degrees C or four hours at room temperature.
Track cumulative prefilled storage time
Keep prefilled Xolair in its carton at 2 to 8 degrees C, protected from sunlight. It may return to refrigeration, but cumulative time outside refrigeration cannot exceed two days. Do not use after freezing or exposure above 25 degrees C. Refrigerating again does not reset the clock.
Act on systemic omalizumab reactions
Stop Xolair for severe hypersensitivity or a serum-sickness-like combination of fever, rash, joint symptoms and lymphadenopathy. Assess eosinophilia with vasculitic rash, worsening breathing, cardiac symptoms or neuropathy, especially during steroid reduction. Avoid abrupt corticosteroid withdrawal. Monitor patients at high geohelminth risk. Xolair treats neither acute bronchospasm nor emergency anaphylaxis.
Explain omalizumab safety uncertainty accurately
Early studies showed a malignancy imbalance; later observational rates were similar but could not exclude risk. An observational cardiovascular/cerebrovascular signal was limited by confounding and other design problems. Shorter pooled randomized trials neither confirmed nor ruled it out. Discuss these uncertainties without presenting causation as established or risk as disproven.
Quick check
Checking for saved practice…
Lesson
Acute Exacerbations, Action Plans, and Follow-Up
An exacerbation is acute or subacute worsening in symptoms and lung function. Treatment restores oxygenation and airflow, suppresses inflammation, identifies life threats, and closes the prevention loop.
- Severity assessment
- Bronchodilator and ICS
- Systemic corticosteroid
- Anaphylaxis
- Discharge and action plan
Speech, effort, oxygen, airflow, mental status, and quiet chest
Rapid bronchodilator; oxygen for hypoxemia; adjuncts by severity
ICS-containing regimen, technique, action plan, and early follow-up
Recognize severity before silence
Assess respiratory rate, pulse, speech, accessory muscles, mental status, oxygen saturation, PEF or FEV1 when feasible, and response to initial therapy. For patients younger than 18, include a validated severity score such as PRAM and repeat it during reassessment. A quiet chest, exhaustion, drowsiness, confusion, cyanosis, poor respiratory effort, or rising carbon dioxide indicates life-threatening airflow limitation and need for urgent escalation.
Treat airflow and inflammation
Give repeated inhaled rapid bronchodilator through an effective device, add ipratropium for moderate or severe attacks or inadequate initial SABA response, provide controlled oxygen when hypoxemic, and give systemic corticosteroid promptly for moderate or severe exacerbation or incomplete response. GINA 2026 permits ICS-formoterol as an alternative reliever for selected mild acute presentations, subject to age, local protocol, and product context.
Dose initial bronchodilation by severity
In the GINA 2026 primary-care pathway for ages 6 and older, salbutamol (albuterol) doses assume 100 mcg per actuation through pMDI plus spacer. Mild presentations receive four puffs, with one repeat after 30 to 60 minutes if needed. Moderate presentations receive four to six puffs or 2.5 mg nebulized, repeated up to three times 20 to 30 minutes apart. Give spacer puffs individually and shake before each.
Treat severe attacks while arranging transfer
Severe or life-threatening presentations require immediate transfer arrangements and continuous monitoring. Give six to ten salbutamol puffs or 5 mg nebulized, repeating every 20 to 30 minutes if needed. When available, add four ipratropium puffs of 20 mcg with salbutamol for up to three treatments. Confirm local product strengths; these are supervised acute-care instructions.
Reassess before considering discharge
Review response within one hour or sooner. Discharge assessment includes sustained improvement to mild clinical features for one to two hours after the last salbutamol, adequate room-air oxygenation, improving PEF above 70% of personal best or predicted, and sufficient home support. A single reassuring measurement is insufficient.
Avoid automatic tests and sedatives
Chest radiographs, blood gases and antibiotics are not routine for every asthma attack. Order investigations when the presentation, suspected complication or response warrants them. Do not use sedatives during an exacerbation. Persistent deterioration requires higher-level care rather than repeated treatment without reassessment.
Reserve IV magnesium for selected severe disease
IV magnesium sulfate is not routine first-line treatment. GINA supports considering it after inadequate initial response with persistent hypoxemia, including adults presenting with FEV1 below about 25% to 30% predicted. An adult regimen is a single 2 g infusion over 20 minutes in monitored acute care. Do not substitute nebulized magnesium, which has not shown significant benefit. Pediatric dosing requires an age-appropriate protocol.
Use a pediatric magnesium protocol
For children older than one year with incomplete response during the first one to two hours, the Canadian Paediatric Society lists IV magnesium sulfate 40 to 75 mg/kg over 20 to 30 minutes, capped at 2.5 g. This is a named pediatric protocol, not a universal dose or an adult fixed-dose substitution. Consult pediatric emergency or intensive care staff and monitor cardiorespiratory status, including blood pressure and heart rate, for hypotension or bradycardia.
Recognize the limits of noninvasive ventilation
Evidence for NIV in acute asthma remains limited. If an experienced acute-care team trials it, close monitoring is essential. Do not use sedation to make an agitated patient tolerate NIV. This differs from the stronger established role of NIV in appropriate COPD exacerbations; an asthma trial must not delay necessary airway escalation.
Specify the short systemic steroid course
GINA 2026 recommends adult prednisolone 40 to 50 mg each morning for five to seven days. For children ages 6 to 11, use 1 to 2 mg/kg/day, capped at 40 mg, for three to five days. These are acute courses, not maintenance regimens. An isolated course under two weeks generally needs no taper; evaluate existing long-term steroid exposure separately.
Choose the systemic steroid route deliberately
Give systemic corticosteroid within the first hour when indicated. Oral therapy is as effective as IV therapy and is preferred when swallowing and absorption are reliable. Vomiting, inability to swallow because of dyspnea, or ventilatory support can justify IV administration. Clinical benefit takes several hours, so corticosteroids do not replace immediate bronchodilation.
Titrate oxygen and arrange reassessment
For a nonpregnant adult acute presentation, GINA 2026 targets oxygen saturation of 92% to 95% when supplemental oxygen is needed. Pulse oximetry can overestimate saturation in hypoxemic people with dark skin; interpret it with the clinical examination. After discharge, arrange adult follow-up within two to seven days and child follow-up within two to five days. Worsening requires earlier urgent reassessment.
Give epinephrine first for anaphylaxis
When wheeze accompanies anaphylaxis, give epinephrine immediately and activate emergency care. Intramuscular administration remains standard in clinical resuscitation; GINA also recognizes nasal epinephrine. Use the appropriate available product and emergency plan, then add bronchodilators and supportive care as indicated. Inhaled albuterol does not treat hypotension, upper-airway edema, or mast-cell mediator release.
Apply nasal epinephrine instructions precisely
Neffy is labeled for anaphylaxis from 15 kg: one 1 mg nasal spray at 15 to less than 30 kg, or one 2 mg spray at 30 kg or more. The March 2026 label removed the previous age minimum. Carry two devices. If symptoms fail to improve or worsen, a second new device may be used in the same nostril starting five minutes later; more than two sequential epinephrine doses require direct medical supervision.
Teach the single-use nasal device
Do not prime or reuse Neffy. Insert the nozzle fully, point straight, and press firmly; avoid sniffing during and after administration. Nasal polyps, prior fractures or surgery may alter absorption, so consider another epinephrine route. Follow the emergency plan for immediate assistance and monitoring. Nasal doses are not interchangeable milligram-for-milligram with injected doses.
Use personal-best zones correctly
A peak-flow action plan uses the patient's personal best, not the diagnostic diary denominator. NHLBI zones are green at least 80%, yellow at least 50% but below 80%, and red below 50% of personal best. For a personal best of 500 L/min, the cutoffs are 400 and 250 L/min. Record flow in L/min, not volume in mL. Follow the individualized medication and contact instructions. Severe breathing difficulty, trouble speaking or walking, or blue lips require emergency help regardless of a reassuring meter reading.
Select ongoing treatment after emergency care
After an emergency visit or hospitalization, GINA favors ICS-formoterol maintenance-and-reliever therapy for adults and adolescents; starting at Step 4 can be appropriate after this acute-care event. Medium-dose ICS-LABA maintenance is the alternative when MART is unavailable. Specify the product, maintenance dose and total daily inhalation limit. Review recovery and control before later step-down, generally after two to three months of stability. Arrange specialist assessment after hospitalization or repeated acute-care presentations. More than one oral steroid course in the past year also warrants expert advice.
Choose a child's discharge regimen explicitly
For ages 6 to 11, GINA's post-exacerbation Step 4 options include medium-dose ICS-LABA maintenance with an as-needed reliever, or age-appropriate ICS-formoterol MART. Confirm the child's formulation and dosing schedule rather than borrowing an adult prescription. Local product approval still matters when selecting SABA or ICS-SABA relief.
Return reliever treatment to symptom-driven use
At discharge, explain which inhalations remain scheduled maintenance and which are taken only for symptoms. Routine reliever dosing can obscure deterioration. Provide an interim written plan for the next few days, and continue follow-up until symptoms and lung function recover.
Prevent the next attack
Before discharge, confirm improvement and safe oxygenation, supply an ICS-containing regimen and adequate medicines, check technique, remove avoidable triggers, provide a written action plan, state maximum reliever use and emergency thresholds, and arrange early follow-up. Review each exacerbation for modifiable contributors without assuming every attack was preventable.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 174 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- GINA 2026 Summary Guide, Table 6: age- and formulation-specific metered ICS dose categories
- Primatene Mist Drug Facts, revised June 2026
- NHLBI EPR-3: airway pathophysiology and remodeling (2007 background)
- Theophylline oral solution labeling: formulation-specific historical loading context
- Atrovent HFA prescribing information, revised December 2024
- Fluticasone HFA safety and interactions: November 2024 prescribing text, January 2026 repackaged label
- Aurobindo albuterol 0.63 mg/3 mL and 1.25 mg/3 mL prescribing information
- CDC: influenza clinical considerations, September 2026
- CDC: pneumococcal risk-based recommendations, May 2026
- CDC: routine pneumococcal vaccination recommendations
- NAEPP 2020 focused updates: immunotherapy, clinician guide page 7
- Odactra prescribing information, revised June 2026
- Teva November 2022 announcement: ProAir HFA marketing discontinuation
- Teva: US Digihaler distribution and app discontinuation, June 2024
- AeroChamber Plus Flow-Vu Canadian instructions, 103077-001 Rev B
- AeroChamber Plus non-antistatic UK instructions, 117016-001 Rev B
- NHLBI: So You Have Asthma (2007), peak-flow technique and personal best, pages 30 to 32
- Serevent Diskus prescribing information
- Ventolin HFA prescribing information
- Xopenex HFA prescribing information and device instructions
- Xopenex inhalation solution prescribing information
- Xopenex concentrate prescribing information
- Canadian Paediatric Society: acute pediatric asthma and medication dose table
- GINA 2026 Strategy Report: treatment, specific populations and exacerbations
- Wixela Inhub prescribing information and instructions
- Advair HFA prescribing information and instructions
- Breztri Aerosphere prescribing information and instructions for use (April 2026)
- Trelegy Ellipta prescribing information
- Breo Ellipta prescribing information
- Asmanex HFA prescribing information and instructions
- Asmanex Twisthaler prescribing information and instructions
- Fluticasone propionate Diskus prescribing information and instructions
- Arnuity Ellipta prescribing information
- Fluticasone propionate HFA prescribing information
- Alvesco prescribing information and instructions
- Zyflo immediate-release prescribing information
- Aminophylline injection prescribing information
- Exdensur prescribing information, June 2026
- Xolair prescribing information, asthma dosing and self-administration criteria, August 2026
- Tezspire prescribing information, indication, dosing and safety
- Nucala prescribing information
- Cinqair prescribing information
- Fasenra prescribing information
- Dupixent prescribing information, asthma dosing sections 2.3 and 2.4, warnings section 5 and mechanism 12.1
- Pulmicort Respules prescribing information and instructions
- Advair Diskus prescribing information and instructions
- AirDuo RespiClick prescribing information and instructions
- ProAir RespiClick prescribing information and instructions
- Symbicort conventional aerosol prescribing information and instructions
- Symbicort Aerosphere FDA label and instructions, April 2026
- Dulera FDA prescribing information, revised June 2025, dosing and instructions
- GINA 2026 Strategy Report
- GINA 2026 Summary Guide
- GINA 2026 Severe Asthma Guide
- NHLBI Asthma Action Plan
- Neffy Prescribing Information (March 2026 revision)
- Airsupra Prescribing Information (DailyMed, revised September 2025)
- Albuterol 0.5% concentrate labeling (Rising)
- Albuterol 0.083% ready-to-use labeling (Ritedose)
- Orkambi prescribing information: montelukast interaction, section 7.6 (2026)
- Singulair prescribing information
- Zafirlukast prescribing information
- Zileuton extended-release prescribing information
- Lupin albuterol aerosol prescribing information and instructions
- Ritonavir prescribing information: theophylline interaction
- Primidone SmPC: interaction section4.5
- Fosphenytoin prescribing information: interactions
- Levothyroxine prescribing information: methylxanthine interaction
- Theo-24 prescribing information
- Spiriva Respimat US prescribing information
- QVAR RediHaler prescribing information and instructions
- Pulmicort Flexhaler prescribing information and instructions
- FDA Montelukast Drug Safety Communication
- FDA Current Asthma Product Labeling
- DailyMed Current Medication Labeling